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Abstract 
Mutagenesis of Human α-Galactosidase A for the Treatment of Fabry Disease 
 
By 
Erin Stokes 
Advisor: Dr. David Calhoun 
 
 Fabry disease is an X-linked lysosomal storage disorder caused by the deficiency of the 
enzyme, α-galactosidase A, which results in the accumulation of the lipid substrate.  This 
accumulation results in obstruction of blood flow in patients and early demise at approximately 
40-60 years of age.  There is currently only one FDA approved treatment (Fabrazyme) classified 
as an enzyme replacement therapy.  However, approximately 88% of patients experience a 
severe immune response that, rarely, can be fatal and is a huge cost burden at average $250,000 a 
year per patient.  The structure of α-galactosidase A has been previously determined to be a 
homodimer with six N-linked glycosylation sites, and the catalytic mechanism determined to be 
a ping-pong bi-bi with the second substrate being water.  The purpose of this research is twofold:  
first, to generate a more efficient enzyme replacement therapy alternative; and second, to 
develop an alternative assay to detect the activity of the enzyme that can lead to a better screen 
for the presence of lysosomal storage disorders in patients.  A more efficient therapy was 
investigated utilizing two different host expression systems, Escherichia coli and Pichia 
pastoris, as well as site directed mutagenesis of the human enzyme.  Detectable expression was 
not observed in E. coli, so mutagenesis was carried out using P. pastoris.  Three locations on the 
structure of α-galactosidase A protein were targeted for mutation the active site, the dimer 
interface, and the hydrophobic loop between the active site and the third glycosylation site.  
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Viable candidates for further study into a therapeutic α-galactosidase A were determined based 
on catalytic efficiency (kcat/Km), thermostability, and possible glycosylation independence.  
Three mutations were identified to be of potential therapeutic significance in each one of the 
targeted areas.  A continuous enzyme assay was developed with an artificial fluorescent 
substrate, 4-methylumbelliferyl-α-D-galactopyranoside, that at acidic pH generates the same 
kinetic values as the preexisting discontinuous time point assay at basic pH.  This development 
has not only potential laboratory benefits if implemented; it also has a clinical significance in 
screening for Fabry disease and can potentially be extended to other lysosomal storage disorders.  
vi 
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 Introduction Chapter 1
 Fabry Disease is a rare X-linked genetic lipid storage disorder caused by an absence or 
deficiency of the enzyme α-galactosidase A (α-Gal) in humans.  This enzyme is primarily 
responsible for the cleavage of the terminal α-galactose from the lipid globotriaosylceramide 
(Gb3) in the lysosome (5).  In Fabry disease, this substrate accumulates in membranes of the 
lysosome as well as in the endoplasmic reticulum, cell membrane, and the nucleus leading to a 
series of membrane ring-like formations.  This event leads to an increase in capillary thickness 
with a distinct arteriosclerotic change, particularly apparent in the kidneys and brain, which 
decreases blood flow.  The heart wall thickens (cardiac hypertrophy) as well causing the patient 
to experience pain and ultimately resulting in myocardial infarction, renal failure, and strokes, 
leading to an early death to the patient at ages 40-60 (6).  Currently only one FDA approved 
treatment for Fabry disease exists (Fabrazyme), which is an enzyme replacement therapy (ERT).  
This treatment involves intravenous infusions typically once every two weeks often resulting in 
severe side effects and immune responses that can be fatal.  This therapy is also extremely 
expensive costing on average $250,000 a year per patient (7).  A safer, more effective, and more 
affordable therapeutic needs to be made available for patients.  Mutation of human α-Gal has 
the potential to result in a more effective therapeutic for patients with Fabry disease. 
Fabry Disease Background and Prevalence: 
 Fabry disease is a disease caused by the absence or deficiency of the enzyme α-Gal, 
which is the result of a mutation in the gene GLA on the X chromosome.  This deficiency results 
in a glycosphingolipid metabolism disorder and falls into the category of a lysosomal storage 
disorder, due to the main location of the accumulation of the substrate Gb3 (5).  There are over 
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40 different lysosomal storage disorders, with Fabry disease being the second most common (5).  
Unlike many other diseases of this class, for example Tay Sachs, Fabry disease patients can be 
asymptomatic in early life. The initial symptoms include chronic pain, skin lesions, 
gastrointestinal disorder, and vascular deterioration.  The main organs where the effects of the 
accumulation are observed are the blood vessels, skin, heart, kidneys, and the nervous system.  
Later in life the disease causes life threatening and eventually fatal conditions such as renal 
failure, stroke, and myocardial infarction (5). 
Globally the prevalence of Fabry disease was initially thought to be 1 in 40,000 to 1 in 
60,000 males for the classic form of the disease, which is defined as no detectable α-Gal activity.  
The disease is considered to primarily affect males; however women who are heterozygous for 
the trait are not only carriers, but due to random X chromosomal inactivation can also suffer 
from Fabry disease in a huge variation of mild to severe (8).   A random screening of 37,104 
newborns for Fabry disease in Italy indicated the prevalence in males to be 1 in 3,100 (9).  The 
large difference in statistics was explained as being due to the inclusion of often undiagnosed 
patients with residual but low activity of α-Gal, referred to as the non-classic form of Fabry 
disease (late onset) with the ratio of late onset to classical being 11 to 1 (9).  A random screening 
of 110,027 newborns in Taiwan discovered the incidence in males to be about 1 in 1,500 (10).    
This study determined there were still significantly fewer females affected than males, with 
approximately 1 in 17,000 affected, this prevalence is still a much greater incidence than was 
previously thought for males (10).  While lysosomal storage diseases are individually rare, the 
cumulative incidence of known patients and the undetected reservoir of undiagnosed patients 
with these diseases constitute a significant total incidence of disease with a large societal impact. 
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Structure and Catalytic Mechanism of α-Gal: 
 The structure of human α-Gal determined by X-ray crystallography (Figure 2) is a 
homodimer, with each subunit containing two domains in a head-to-tail configuration (2).  The 
catalytic site located in the N-terminal domain is in an (α/β)8 domain.  The second domain 
contains the C-terminus and is an 8 antiparallel β-sheet barrel.  The large and small domains of 
the monomer have a large interface, shielding 2,500 Å
2
 of surface area. The dimer has a slightly 
smaller interface between the monomers only covering 2,200 Å
2
 of surface.  There are 30 
residues from each monomer in six loops involved in the interface formation of the dimer into a 
concave structure.  Also N-linked glycosylation sites are found on six different residues on the 
surface of the protein (three per monomer) (Figure 4, 13).  The catalytic mechanism of human α-
Gal was determined in 2010 also using X-ray crystallography (1).  The reaction is a ping-pong 
bi-bi reaction, with the two substrates being Gb3 and water. Residues, Asp170 and Asp231, 
participate in two separate nucleophilic attacks on the anomeric carbon allowing for the cleavage 
of the terminal galactose (Figure 1).  Although these are the only two residues participating 
directly in the actual cleavage mechanism, many other residues in the active site are involved in 
the process through hydrogen bonding or hydrophobic interactions, such as Trp47, Asp92, 
Asp93, Tyr134, Cys142 bridged to Cys172, Lys168, Glu203, Tyr207, and Arg227 (Figure 9, 
page 31).  Mutations in anyone of these residues could potentially impact the efficiency of the 
catalytic mechanism (1). 
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Figure 2. Crystal structure of human α-
Gal. (2) 
a) Ribbon structure of the monomer 
containing two domains and the active 
site.  b, c) Ribbon structure of the 
dimer containing two active sites on the 
interface.  d) Electrostatic map of the 
dimer, red is negatively charged, white 
is neutral, blue is positively charged, 
and green is carbohydrates.  
 
Figure 1. Catalytic mechanism of α-Gal. (1) 
The substrate with the terminal α-galactose enters the 
catalytic site and under goes two nucleophilic attacks 
in series, with water entering as a second substrate 
and the remainder of the molecule leaving as the first 
product.  
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Current Treatments and Challenges: 
 Today two ERTs are available for Fabry disease.  One, designated agalsidase beta 
(Fabrazyme Genzyme, Cambridge, Massachusetts), is FDA approved, and is produced in 
Chinese hamster ovarian cells (11).  The other, agalsidase alfa (Replagal, Shire Human Genetic 
Therapies, Cambridge, Massachusetts) is approved worldwide but did not receive FDA approval 
for use in the US.  Replagal is produced by a stably transfected human diploid fibroblast cell line 
designated DRX005A (12).  The amino acid sequence of these therapeutic enzymes is identical 
but they differ in the pattern of glycosylation.  Fabrazyme and Replagal both contain mannose-6-
phosphate glycosylation (2).  It was previously assumed that terminal mannose-6-phosphate 
glycosylation was necessary for effective therapeutic cell uptake and targeting to the lysosome, 
however more recently evidence was presented that alternative uptake pathways are involved in 
Fabry disease (13).  The receptors megalin and sortilin account for greater uptake of α-Gal in 
podocytes, clinically relevant cell lines, as opposed to fibroblasts used previously (13). Further 
research identified the mannose receptor to increase uptake in endothelial cells, also disease 
relevant (14).  These treatments pose a huge economic burden with their costs.  The average cost 
in the last decade for ERT is $250,000 a year per patient (7).  Treatments generated from 
mammalian cell lines are severely expensive because they cost so much to produce.  This same 
enzyme produced in E. coli or P. pastoris would be much less expensive to produce and 
therefore be more affordable, thereby reducing the economic burden for healthcare. 
The clinical efficacy of Fabrazyme and Replagal has been demonstrated (8, 15, 16).  
However, it has also been shown that many patients respond to ERT with an immunoglobulin G 
(IgG) response. Results from clinical trials with Fabrazyme indicate that 88% of male patients 
developed IgG responses to infusions (17) while clinical trials with Replagal indicate that 56% of 
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male patients have IgG responses (18).  These results are not directly comparable however, 
because the antibody titers were generated using different assays.  The effects of these antibodies 
manifest visible symptoms in patients such as chills, fever, pain, and hives (19).  This response 
has been shown to decrease the long-term effectiveness of the drug, based on Gb3 levels 
analyzed from patients’ skin (20).  Replagal, with an infusion dose of 0.2 mg/kg every other 
week, was compared to Fabrazyme at both the prescribed dose of 1 mg/kg every other week, and 
the same, 0.2 mg/kg every other week, dosing as Replagal, and it was observed that the adverse 
effects were more correlated to dosage than type of treatment (21).  Since dosage is involved in 
IgG response, having a therapeutic that is more catalytically active would allow for a lower 
dosage for the patient, this theoretically would cause the immune response to be less severe, if at 
all. 
Glycosylation is very crucial in the immunogenicity of biomolecules (4).  It can either 
protect or enhance an immune response depending on the protein and the carbohydrate bound to 
it.  This is extremely important in the design of biopharmaceuticals, because it has been shown 
that heterologous glycosylation can bring about neutralizing antibodies (4) as seen in the case of 
commercially available α-Gal.  Normal human-type glycosylation can avoid an immune response 
mostly by creating a more stable protein, which is more soluble and less likely to aggregate (22).  
As stated before, the only difference between Fabrazyme and Replagal is the glycosylation 
pattern and, although not conclusively, it has been observed that Replagal generates less of an 
immune response than Fabrazyme (20).  Therefore, it can be hypothesized that if there is no 
glycosylation present on the therapeutic, it decreases the likelihood of neutralizing IgG rendering 
the enzyme inactive.  If the protein is mutated in such a way that it is stable without the presence 
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of carbohydrates, then it will not need the glycosylation to protect the therapeutic from 
immunogenicity. 
Current ERT does permit α-Gal to cross the blood brain barrier, which is detrimental in 
the case of Fabry disease because there are neurological symptoms that cannot be addressed with 
treatment (23).  However, a study of chemically treated β-glucuronidase, an ERT for 
mucopolysaccharidosis VII, with sodium metaperiodate followed by a sodium borohydride 
reduction to modify the glycosylation, rendered it unable to undergo uptake by the mannose-6-
phosphate receptor.  Treatment with this modified ERT showed a decrease in the accumulated 
substrate from the brain in a mouse model (24).  This discovery led to the hypothesis that 
glycosylation can be an obstacle in the crossing of ERT through the blood brain barrier.  
 Clinical trials are underway for additional ERTs such as human α-Gal produced in plants 
(Moss-α-Gal) produced by Greenovation Biopharmaceuticals and pegunigalsidase alfa produced 
in tobacco by Protalix.  Moss-α-Gal is human α-Gal produced in moss, which results in mannose-
terminated glycosylation, the same as P. pastoris, and has shown improvement in uptake in disease 
relevant cells (14).  Pegunigalsidase alfa is produced in tobacco, which also is mannose terminated, 
and is chemically crosslinked with polyethylene glycol and has been shown to be more stable and 
have increased half-life in plasma (25). 
 In addition to ERT, molecular chaperones such as Migalastat produced by Amicus 
Therapeutics, are in late stage clinical trials.  The benefit of chaperone therapy is the ability to 
treat tissues that are unable to take up current ERTs such as the kidneys and brain, however the 
drawback is that chaperone treatment only works for specific mutations in the GLA gene (26).  
Substrate reduction therapy such as Ibiglustat (Genzyme) is another treatment currently in 
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clinical trials.  It is similar to Migalastat in the sense that it is a small molecule and not a biologic, 
Ibiglustat, however, inhibits the production of Gb3 (27) instead of increasing the clearance of Gb3 
like ERT or chaperone therapy.  Earlier this year a patient received treatment with gene therapy for 
Fabry disease (28), which has been under consideration in the past(29). 
Glycosylation 
Human α-Gal has six sites of N-linked glycosylation (22).  Each monomer contains three 
glycosylation sites: Asn139, Asn192, and Asn215.  One distinctive thing about human α-Gal, as 
opposed to some of the orthologs, is that glycosylation is required for solubility in the natural 
form.  Asn215 must be glycosylated for the protein to be soluble in an aqueous solution. 
Although Asn192 improves the secretion of the enzyme, the other glycosylation sites are not 
absolutely necessary for solubility (2, 3).  The removal of glycosylation at sites Asn139 and 
Asn192 decrease the activity of the enzyme, but it has been previously reported to contain more 
than 70% of the original activity (3).  Asn215 is located near the entrance of the active site, with 
a hydrophobic loop in between Asn215 and residue Tyr207, an active site residue (Figure 4). 
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Figure 3. Hydrophobicity map of primary sequence near Asn215(3). 
Asn215 is located at position 21 (circled), Tyr207 is located at position 13 (circled) and 
all residues before, are either in the active site or buried.  Met208 (14) to Phe211 (17) is 
in a surface exposed loop. 
 
Figure 4. Three dimensional structure of the location of the hydrophobic 
loop.   
The magenta portion is Met208 to Phe211, the cyan is the rest of the 
protein, and the red are the carbohydrates.  The structure is 3HG4 from 
PDB(1). 
Asn215 Tyr207 
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Homology 
Human α-Gal does not possess the theoretical maximal possible catalytic efficiency based 
on diffusion limited reactions.  The average literature values for the Vmax and Km of human α-Gal 
are 3.4 mmoles/hr per mg and 2.4 mM respectively, which through a series of calculation shown 
below, results in a turnover number (kcat) of 85 s
-1
 and a specific constant (kcat /Km) of 3.54x10
4
 
M
-1
s
-1
.   
3.4
𝑚𝑚𝑜𝑙𝑝𝑟𝑜𝑑𝑢𝑐𝑡
𝑚𝑔𝑝𝑟𝑜𝑡𝑒𝑖𝑛ℎ𝑟
𝑥
1ℎ𝑟
3600𝑠
𝑥
1𝑚𝑜𝑙𝑝𝑟𝑜𝑑𝑢𝑐𝑡
1000𝑚𝑚𝑜𝑙𝑝𝑟𝑜𝑑𝑢𝑐𝑡
𝑥
1000𝑚𝑔𝑝𝑟𝑜𝑡𝑒𝑖𝑛
1𝑔𝑝𝑟𝑜𝑡𝑒𝑖𝑛
𝑥
90000𝑔𝑝𝑟𝑜𝑡𝑒𝑖𝑛
1𝑚𝑜𝑙𝑝𝑟𝑜𝑡𝑒𝑖𝑛
= 85𝑠−1  1 
 
The molecular weight of the human α-Gal native dimer is approximately 90 kDa.  The average 
values for Vmax and Km were determined from the table of literature values of human α-Gal from 
a compilation of sources(30).  The optimum diffusion controlled efficiency of an enzyme is a 
specific constant (Kcat/Km) in the range of 10
8
 to 10
9
 M
-1
s
-1
, indicating that there is an apparent 
possibility for improvement in catalytic properties for the normal human α-Gal. 
 The literature contains kinetic data on α-Gal homologs (31) that have greater catalytic 
efficiency (Kcat/Km) compared to the human enzyme (Table 2).  This further illustrates that the 
human enzyme has a capacity to have a greater intrinsic catalytic activity. 
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Table 2. Comparison of the activity of homologs to human α-Gal (30). 
 
  
PubMed 
Accession code Genus and species 
Colloquial 
Name 
Km 
(mM) 
Kcat  
(s
-1
) 
kcat/Km 
(M
-1
 s
-1
) 
Relative 
kcat/Km 
BLAST 
%Identity 
NP 000160 Homo sapiens Human 6.88 37.8 5490 1 100 
NP 038491 Mus musculus Mouse 1.4 N/A N/A N/A 78 
WP 
004844583.1 
Ruminococcus 
gnavus Bacteria 1.8 30.1 16700 3 28 
AAC99325 
Saccharopolyspora 
erythraea Bacteria 0.65 23.3 35800 6 39 
P41947 
Saccharomyces 
cerevisiae Yeast 4.5 286 63600 12 33 
BAB83765 
Clostridium josuil 
(Catalytic Domain) Bacteria 0.81 61.9 76400 14 46 
AAG24511 
Phanerochaete 
chrysosporium Fungus 0.198 272 1370000 250 37 
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Expression in Pichia pastoris 
 P. pastoris is a methylotrophic yeast strain that has been successfully been utilized to 
express functional human α-Gal in this lab (32).  A P. pastoris expression vector, pPICZαA, is 
commercially available from Invitrogen that uses the alcohol oxidase (AOX) promoter to produce 
the target protein as well as a Zeocin resistance gene for selection.  This vector can be linearized 
and integrated into the genome of P. pastoris in the AOX gene.  The strain can then use methanol 
as a metabolite and express human α-Gal. 
Site Directed Mutagenesis 
 Often, site specific mutation is used to explore the effect one residue has on a specific 
function and is a much more focused and targeted approach (33).  My research focuses on three 
specific enzyme locations in α-Gal to implement mutations: the catalytic site, the dimer interface, 
and the glycosylation sites.  The catalytic site was investigated to directly increase the activity of 
the enzyme, by introducing mutations that are observed in homologous enzymes with greater 
activity (Table 2).  The dimer interface was explored to evaluate the importance of the stability 
of the dimer in maintaining activity.  The third glycosylation site (Asn215), particularly the 
residues surrounding it, was selected for mutation to test the hypothesis that it may be possible 
stabilize a glycosylation deficient mutant at the third glycosylation site. 
Important Therapeutic Properties 
 A successful candidate for a therapeutic would contain an increase in one, if not more of 
the following three criteria: kinetic activity, stability, and glycosylation independence.  An 
increase in activity is defined as an increase in the efficiency (kcat/Km) of the enzyme and would 
need to be observed with either greater or equal stability as the wild type.  An increase in thermal 
stability is experimentally defined as the greater retention of activity after exposure to increased 
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temperatures.  This increase in stability also needs to be observed with at least the same catalytic 
efficiency as the wild type enzyme.  Glycosylation independence must not compromise either the 
catalytic efficiency or the stability of the enzyme as compared to the wild type.  A summary of 
the mutants constructed for this research divided by location of mutation is displayed in Tables 
3-5. 
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Table 3. Summary of Active Site Mutants 
Mutation 
Purification 
Method 
Rational Image 
Y207W 
DEAE/SP 
Homology 
 
E203C 
E203C/Y207W 
E203N 
Not purified 
E203C/W204C/P205X/
L206X/Y207W 
E203C/W204N/P205X/
L206X/Y207W 
D170C 
Organic  
Chemistry 
Principles 
 
Table 4. Summary of Interface Mutants 
Mutation 
Purification 
Method 
Rational Image 
F273C DEAE/SP 
Thiol/aromatic 
stabilization 
 
W277C 
DEAE/Thio-
gal 
F273G/W277G SP 
Disrupt dimer F273G 
Not Purified 
W277G 
F273C/W277C 
Disulfide linkage 
of dimer F273C/N278C 
 
Table 5. Summary of 3
rd
 Glycosylation Site Mutants 
Mutation 
Purification 
Method 
Rational Image 
M208E/N215Q DEAE/Thio-gal 
Zebrafish 
Homology 
 
M208E/F211H/ 
N215Q 
DEAE/SP 
F211H/N215Q 
Not Purified M208X/N215Q 
Deletion 
Homology 
W209X/N215Q 
F211X/N215Q 
DEAE/SP 
N215Q 
Glycosylation 
Knockout 
M208E DEAE/Thio-gal 
Follow up 
M208E/N215Q 
results 
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 Expression of Human α-Gal in E. coli Chapter 2
Overview 
 This research attempted to conduct mutagenesis experiments in E. coli.  In order to 
accomplish this, expression plasmids of wild type α-Gal were constructed as well as an 
expression strain.  E. coli was investigated initially because of its ease of selection, its cost 
efficiency, and its inability to glycosylate proteins. 
E. coli Expression Strains 
 E. coli contains an endogenous α-Gal so the gene must be inactivated in order to screen 
for the human enzyme in its presence.  Deletion of α-Gal gene, melA, renders E. coli incapable 
of growth on melibiose or the formation of a blue precipitate from 5-bromo-4-chloro-3-indolyl α-
D-galactopyranoside (X-Gal). Human α-Gal contains several disulfide bonds located throughout 
the enzyme including in the active site.  Wild type E. coli does not have the catalytic mechanism 
for the formation of disulfide bonds in the cytoplasm due to the presence of several 
thioreductases.  The expression strain therefore should have mutations that allow for proper 
folding of α-Gal.  Two specific enzymes were characterized, glutathione reductase (gor) and 
thioredoxin reductase (trxB), that when deleted, result in proper folding of some human enzymes 
in the cytoplasm of E. coli (34).  These types of strains are commercially available; however all 
of them contain their own endogenous α-Gal.  The codons for E. coli translation and humans are 
not the same in all cases, which often makes expression of human proteins in an E. coli host 
potentially inefficient.  Human α-Gal contains many codons rarely found in E. coli, so to enable 
expression a plasmid containing 7 tRNAs for human codons was obtained (pRARE). 
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E. coli Expression Vector 
 The cDNA of human α-Gal was determined and contained in a plasmid from previous 
research in this lab (35).  This cDNA was integrated into two different pET expression vectors 
(Novagen) which are widely used expression vectors for E. coli, one targeting the periplasm 
(pET-20b) and the other targeting the cytoplasm (pET-14b).  Both plasmids contained an 
ampicillin (amp) resistance gene for selection purposes.  The vector maps for both plasmids are 
shown in Figures 5 and 6.  These vectors were evaluated to determine if they were capable of 
producing sufficient α-Gal to have melA knockout E. coli sustain growth on melibiose. 
Methods and Materials 
Construction of the Expression Vectors 
 Two different vectors were designed to express human α-Gal: one for the expression in 
the periplasm (pET-20b vector) and one for the expression in the cytoplasm (pET-14b vector).  
The pET expression vectors underwent a double restriction digestion to linearize the plasmids: 
pET-20b was digested with NcoI and EcoRI, and pET-14b was digested with NcoI and XhoI.  
The vector maps for both plasmids are displayed in Figures 5-6.  Both plasmids were then 
purified using 1% agarose electrophoresis to remove the small fragment. 
The α-Gal cDNA, contained in pCC106 (32), was isolated using a plasmid preparation 
with a GeneJET kit.   The α-Gal cDNA was amplified using CloneAmp™ HiFi PCR Premix 
with primers that contained a 15 bp homology with the respective expression vector and an 
approximately 20 bp homology with the α-Gal cDNA.  In the case of pET-20b a one bp 
mismatch (A to C) was designed in the 5’ primer to convert a vector-encoded Met to Leu, the 
codon faithful to the N-terminal sequence of the mature form of human α-Gal.  In the case of 
pET-14b, the 5’ primer contains an additional two nucleotides (GC) that are in neither the vector, 
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nor in the cDNA of α-Gal.  These two nucleotides complete the codon GGC that codes for an 
Ala, therefore, a frame shift mutation does not result.  The resultant α-Gal will contain an 
additional two residues (Met and Ala) on the N-terminus; the Met is necessary to ensure 
translation and the Ala is included because a Met-Leu peptide is almost never posttranslationally 
cleaved and is rapidly targeted for degradation by the cell(36).  Met-Ala is cleaved much more 
frequently and has a longer half-life (37).  Ala is also often cleaved from the N-terminus by heat 
shock protein 31, which demonstrates peptidase activity for N-terminal Ala and Gly(38).  The 
sequence of the amplification primers is displayed in Table 6. 
The amplified insert was purified using spin column purification, and was then combined 
with the vector using the In-fusion HD cloning kit (Clontech), which uses homologous 
recombination to integrate the insert into the vector(39).  These vectors were drop dialyzed and 
transformed into the generated expression strain (see generation of expression strains section) 
and screened using ampicillin (Amp) because both pET vectors contain an Amp resistance gene.  
Transformation was performed using electroporation with a Gene Pulser with procedure for 
electrocompetent cells (32).  Plasmids were isolated from cultured transformants using the same 
GeneJet kit.  The resultant vectors were visualized using 1% agarose electrophoresis for the 
presence of the insert and then sequenced by Genewiz and verified by alignment to the vector 
and the α-Gal sequence using Serial Cloner. 
Table 6.  PCR primers for ligation of wild type α-Gal. 
 
Primer Sequence 
pET-20b 5’ CAGCCGGCGATGGCCCTGGACAATGGATTGGCAAG 
pET-20b 3’ GACGGAGCTCGAATTTTAAAGTAAGTCTTTTAATG 
pET-14b 5’ AGGAGATATACCATGGCCCTGGACAATGGATTGGCA 
pET-14b 3’ CAGCCGGATCCTCGAGTTAAAGTAAGTCTTTTAATG 
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Figure 5. pET-14b expression vector map and cloning region (Novagen) 
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Figure 6. pET-20b expression vector map and cloning region (Novagen) 
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Construction of the Expression Strain 
 Three strains containing the desired mutations for the expression of α-Gal were acquired: 
one was purchased from New England Biolabs, Shuffle, containing deletions in both the gor and 
trxB genes, another from the E. coli stock center, JW4080-3, and the third was purchased from 
Novagen, Rosetta, containing the pRARE plasmid.  JW4080-3 is a melA knockout strain in 
which melA was interrupted by the insertion of a kanamycin (Kan) resistant gene(40).  This Kan 
insertion was moved from the JW4080-3 strain and using homologous recombination, inserted 
itself in the melA gene of the commercially available gor/trxB knock out strain (Shuffle) using 
phage P1vir transduction.  JW4080-3 was infected with phage P1vir to create a lysate.  After 
infection, phage P1vir integrates fragments of the chromosomal DNA of the host at random upon 
lysis.  Infection of a new strain with these phages will contain either the random fragment of the 
previous strain’s chromosome or the viral DNA.  The Shuffle strain was transduced using the 
lysate from JW4080-3 and the resultant mixture was plated on Luria Broth (LB) plus Kan to 
screen the colonies that have gained the Kan resistance insertion, which likely knocked out 
Shuffle’s melA, from methods illustrated in the Cold Spring Harbor Advanced Bacterial 
Genetics Manual(41). Since the melA knock out was generated with a Kan resistance gene and 
the gor/trxB strain is Kan sensitive, screening on plates containing Kan selected only mutants 
that retrieved this fragment of the chromosome.  These colonies were then patched on to M9 
melibiose plates, to confirm the deletion of the melA gene.  After the phenotype was confirmed 
the pRARE plasmid was inserted using electroporation (32).  
21 
 
Detection Methods for α-Gal 
Plate Assays 
 The transformants with the confirmed α-Gal sequence were patched on an agarose plate 
containing M9 media with melibiose as the carbon source, as well as an LB low salt plate 
containing X-Gal, which causes a blue product to be visible upon cleavage with α-Gal(32).  Both 
expression plates were at acidic pH (4.5) to enable the catalysis of human α-Gal.  The expression 
of α-Gal in the pET vector is under the control of the bacteriophage T7 transcription promoter 
that is induced with isopropyl β-D-1-thiogalactopyranoside (IPTG).  IPTG was spread on the 
plates to a final concentration of 0.4 mM, allowed to dry prior to plating, and incubated for two 
days at 35
o
C.  This incubation temperature was chosen due to the temperature sensitivity of the 
melB gene in E. coli that codes for a melibiose transporter protein, which is much less efficient at 
37
o
 C (42).  Melibiose is also transported into the cell via the lactose transporter protein, which 
operates at 37
o
C, however growth at 35
o 
C enables the use of both systems (43).  Growth on M9 
with melibiose as well as the presence of the blue product ensures the presence of functional 
human α-Gal.   
Whole Cell Enzyme Assays 
 The most quantifiable method to determine the activity of α-Gal is by enzyme assay 
using 4-methylumbelliferyl-α-D-galactopyranoside (MUG), a synthetic substrate that after 
excitation at 365 nm results in a fluorescent product that can be measured at a wavelength of 450 
nm.  Activity was measured in units, where one unit is defined as the amount of enzyme required 
to convert 1 nmole of MUG to 4-methylumbelliferone (MU) in one hour at 37
o
C (32).  This 
method is illustrated in Ioannou’s dissertation for whole cells using human enzyme(44).  In the 
studies involving E. coli enzyme, the same procedure was used with optimized assay buffer 
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conditions for E. coli’s endogenous α-Gal (45).  Enzyme in solution can also be assayed using 
MUG (32).  
Results 
Construction of human α-Gal Expression Vectors: 
 The stepwise construction of the expression vectors was analyzed in silico using Serial 
Cloner.  The pET vectors were double digested, pET-20b with NcoI and EcoRI and pET-14b 
with NcoI and XhoI, and visualized and purified using 1% agarose electrophoresis as seen in 
Figure 7-a and b.  The α-Gal sequence was amplified from a previously utilized plasmid with the 
primers illustrated in Table 6 using PCR.  The PCR product was also visualized using 1% 
agarose electrophoresis with a 2 kb reference control band as seen in Figure 7-c.  This amplified 
product and the digested vector were combined as stated in the In-fusion protocol for 
recombination into the plasmid.  These plasmids were drop dialyzed and electroporated into the 
constructed strain and selected on LB low salt with 50 µg/mL Amp.  The colonies were then 
inoculated into LB low salt with 50 µg/mL Amp in a liquid culture and isolated using a GeneJET 
plasmid prep kit.  The plasmid was then digested and ran using 1% agarose electrophoresis to 
verify the presence of the insert (Figure 7-d and e) and then sent out for sequencing with 
universal T7 primers.  Genewiz returned an intact α-Gal sequence located directly after the 
periplasmic signaling peptide in pET-20b and after the Met-Ala in pET-14b that was aligned 
using Serial Cloner. 
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a) b)  
c)  
d)  e)  
 
 
a-Gal 20 a-Gal 14 
 
1 kb 
  1.5 kb 
pET-14  pET-14   pET-14  pET-14 
-Gal    -Gal      uncut       cut          
uncut      cut 
 
 
 
 
 
Figure 7. 1% agarose electrophoresis illustrating (a,b) successful double digestion of pET-14 
and pET-20 c) successful amplification of α-Gal.  d, e) α-Gal pET-20b and α-Gal pET-14b 
plasmids isolated from transformants and digested with Hind III to demonstrate the increase in 
size due to the insertion of α-Gal. 
2 kb 
insert 
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Construction and evaluation of E. coli expression strain 
 Transduction using phage P1vir was used to insert a kanamycin (Kan) resistance 
transposon integrated in the melA gene (gene that codes for E. coli α-Gal) from strain JW4080-3 
into the commercially available strain Shuffle (C3028H) purchased from New England Biolabs 
containing the mutations ΔtrxB (thioreductase), Δgor (thioreductase), Δlon (protease), ΔOmpT 
(protease), and T7 polymerase (CC1017).  The T7 polymerase is used for transcription of the 
human α-Gal gene incorporated in the pET expression vector constructed previously with 
ampicillin (Amp) resistance.  The strain also contains a compatible pRARE plasmid isolated 
from the Rosetta strain purchased from Novagen that contains tRNA for 7 rare codons in E. coli 
but common in humans.  This plasmid contains a gene for chloramphenicol (Cam) resistance.  
The strains containing a plasmid encoding the cDNA of human α-Gal failed to grow on 
melibiose indicating no detectable expression.  The results of construction and expression of 
these strains are summarized in Figure 8. 
 E. coli strain (CSR603) (with an intact melA gene) was grown in liquid culture to 
determine if MUG and/or /MU could be transported to and from the cytoplasm and be detected 
using whole cell assays.  Table 7 displays these results indicating that whole cell assays are a 
viable method of detection of α-Gal activity.  Therefore, the constructed strains were also grown 
in culture and evaluated for human α-Gal expression.  The whole cell assay results were in 
agreement with the plate assay results and also did not result in detectable human α-Gal activity.  
Thus, efforts were initiated to use P. pastoris to monitor α-Gal activity and mutant analysis. 
  
pET-14 
a-gal 
uncut 
pET-14 
a-gal 
cut 
pET-14 
uncut 
pET-14 
cut 
5kb 
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Table 7. Enzyme activity measured in whole cells for E. coli α-Gal. 
Conditions Activity 
(U/mL/µL 
cells) 
CSR603 grown in M9 melibiose 
assayed at pH 4.5 
0 
CSR603 grown in LB low salt 
assayed at pH 4.5 
0 
CSR603 grown in M9 melibiose 
assayed at pH 7.5 
350 
CSR603 grown in LB low salt 
assayed at pH 7.5 
40 
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Day 1 
 
LB+ 34 µg/mL Cam                     LB+50 µg/mL Kan 
 
         LB+ 100 µg/mL Amp          LB 
Day 5 
 
M9 melibiose pH 4.5+IPTG         M9 melibiose pH 7+IPTG            M9 glucose pH 4.5   
Patch Number Host Strain Plasmid (s) melA Human α-Gal Antibiotic 
resistance 
1 Shuffle - + - - 
2 CC1017 - Δ - Kan 
3 Rosetta pRARE + - Cam 
4 CC1018 pET-20 Δ - Kan and Amp 
5 CC1019 pET-14 Δ - Kan and Amp 
6 CC1020 pCC307 Δ + Kan and Amp 
7 CC1021 pCC308 Δ + Kan and Amp 
8 CC1024 pET-20 and 
pRARE 
Δ - Kan, Amp, and 
Cam 
9 CC1025 pET-14 and 
pRARE 
Δ - Kan, Amp, and 
Cam 
10 CC1026 pCC307 and 
pRARE 
Δ + Kan, Amp, and 
Cam 
11 CC1027 pCC308 and 
pRARE 
Δ + Kan, Amp, and 
Cam 
 
 
Patches 1-3 contain the control strains, which are the origin of the expression strains.  Patches 4-7 are all 
strain CC1017 derivatives with the respective plasmid.  Patches 8-11 are the expression strains containing 
the pRARE plasmid.  It is observed that only the host and the pRARE transformants grow on Cam.  Only 
strains derived from CC1017 grow on Kan and only strains containing pET derived plasmids grow on 
Amp.  Only melA+ strains grow on melibiose, no strain containing a plasmid for human α-Gal grew on 
melibiose. 
Figure 8. Patching for expression of human α-Gal. 
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Discussion 
 Functional human α-Gal could not be detected in E. coli despite the location of 
expression (periplasm versus cytoplasm), human tRNA codons, or the ability to produce 
disulfide bonds. We hypothesize that α-Gal was produced but was extremely unstable 
unglycosylated so it was rapidly degraded before it could be detected.  The constructed strain 
grew very slowly, even pre-induction, making it less ideal for production of proteins as well.    In 
January of 2015 Unzueta et al. reported that they were unable to produce functional human α-Gal 
in E. coli as well (46).  That lab applied all the same techniques utilized here, as well as 
additional techniques, and they were still unable to produce detectable α-Gal in E. coli.  For these 
reasons mutagenesis and production was moved to P. pastoris, which is capable of glycosylation, 
secretion, growth at high densities, and is still more cost efficient to produce than mammalian 
cells.  
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 Site directed mutagenesis of human α-Gal in P. pastoris Chapter 3
Overview 
 Three locations were investigated for potential therapeutic improvement to α-Gal: the 
active site; the dimer interface; and the surrounding region of the third glycosylation site.  The 
blue/white screen offers an accurate but qualitative analysis of each mutant’s respective activity.  
As such there is no certainty that the activity observed is a result of a more/less efficient enzyme 
or due to  more/less abundance of production.  Also in the case of increase of efficiency, there is 
no way to determine if this is a result of an increase in binding affinity of the substrate (Km), 
catalytic activity (Vmax), or even an increase of stability.  To address these issues, all the interface 
mutants as well as the mutants giving a positive/blue result in the initial screening were subjected 
to further screening.  This involved culturing in shake flasks, purification, thermostability 
analysis and kinetic analysis identifying the parameters (Km, Vmax, and kcat).  The kinetic analysis 
was conducted using a newly developed continuous assay using the artificial substrate MUG, 
discussed in depth in Chapter 4.  In the case of one of the interface mutants, the quaternary 
structure was evaluated using size exclusion chromatography and native PAGE.  The most 
promising of these mutants were then selected for scaled up production in a bioreactor, followed 
by purification and in depth analysis. 
Active Site Mutants 
 The active site was selected to potentially increase catalysis.  Active site mutations were 
identified using homology modeling using published values for homologs with increased kinetic 
efficiency compared to the human.  Table 2 (Chapter 1) contains the species that were chosen for 
comparison to human α-Gal and their kinetic data.  Only the crystal structure for α-Gal from 
humans and S. cerevisiae were previously determined (47).  Active sites for the other homologs 
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were determined using homology modeling with the program Protein Homology / 
analogY  Recognition Engine (PHYRE) as well as primary sequence analysis using 
ClustalOmega.  These structures were then compared to human α-Gal using PyMOL to identify 
the residues in the active site.  Figure 9 (a) indicates the active site for human α-Gal and Figure 9 
(b) indicates the residues that were determined to be different in the respective homologs.  R. 
gnavus was excluded from the Table because the predicted structure varied greatly from that of 
the human enzyme.  M. musculus was also excluded because the active site is predicted to be 
identical to that of the human enzyme. 
It was also observed that in addition to the residues Glu203 to Cys203 (E203C) and 
Tyr207 to Trp207 (Y207W) being different in the homologs, that the secondary structure at that 
location in the active site was also altered as well.  In the human enzyme the primary sequence 
containing those two active site residues is EWPLY, and the secondary structure is an alpha 
helix.  In the studied homologs, this same region is a disordered loop containing the residues 
CCW (C. josuil) or CNW (S. cerevisiae and P. chrysosporium).  These mutations were 
constructed to also determine if this predicted secondary structure change resulted in an 
alteration of activity. 
 An additional active site mutation was considered, Asp170 to Cys170 (D170C), which is 
the first of two Asp residues that are directly involved in the catalytic mechanism.  Human 
residue D170 is responsible for the initial nucleophilic attack on the anomeric carbon of 
galactose (1).  A mutation of this residue to a Cys was selected because it was hypothesized 
(Kevin Ryan, personal communication) that a thiol would act as a better nucleophile than a 
hydroxyl, ultimately increasing the rate of the initial step.  The PHYRE program was used to 
predict the 3 dimensional structure of human α-Gal with the active site mutations E203C and 
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Y207W displayed in Figure 10, D170C (Figure 11).  These predictions were carried out to 
determine if there was a predicted adverse structure change with the implementation of these 
mutations. 
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Figure 9. a)  ChemDraw image of human α-Gal active site bound to the 
product galactose.  The blue dotted lines represent hydrophobic 
interactions and the red lines represent hydrogen bonds.  b) Table of 
homologs comparing the relative efficiency to different residues present 
in the active site.  The number system is based on the human α-Gal. 
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Figure 11. Superimposition of wild type human α-Gal (1) 
with the projected structure of the mutant D170C from 
PHYRE.  Image generated using PyMOL. 
Figure 10. Superimposition of wild type human α-Gal (1) 
with the projected structure of the mutant E203C/Y207W 
from PHYRE.  Image generated using PyMOL. 
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Interface Mutations 
 The interface was selected to evaluate the importance of the dimer to the stability of the 
enzyme.   A covalently polyethylene glycol linked dimer is in clinical trials that has an increased 
of stability of the enzyme (25).  Two residues were identified in the dimer interface, Phe273 
(F273) and Trp277 (W277) that were predicted to participate in the formation of the α-Gal 
homodimer.  It has previously been claimed (48) that a mutation in both of these residues to a 
Gly results in a monomeric species that is still functional catalytically.  The benefit of a 
potentially monomeric therapeutic is the prospective uptake into podocytes (kidney cells) in vivo, 
which the current therapeutics are unable to achieve(48).  This research explored the possibility 
of a disulfide linked dimer through a mutation of the previously identified residues to Cys and 
comparing that to the monomer (Gly) as well as the wild type enzyme. It has previously been 
reported that a thiol/aromatic interaction has the ability to stabilize proteins(31) so single Cys 
mutants were constructed as well (F273C and W277C).  Another potential disulfide bound 
mutation was identified using the program MOdelling of Disulfide bond In Proteins (MODIP) at 
Phe273Cys/Asn278Cys (F273C/N278C).  PHYRE was again used to predict the 3 dimensional 
structure of human α-Gal with the interface mutations F273C and W277C displayed in Figure 
12A, F273G and W277G in Figure 12C, and Swiss-Model was used for F273C and N278C in 
Figure 12B. 
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A)  B)  
C)   
 
 
            
            
Figure 12. A) Superimposition of wild type 
human α-Gal (1) with the projected structure of 
the mutant F273C/W277C form PHYRE.  Image 
generated using PyMOL.  B) Projected structure 
of the mutant F273C/N278C from Swiss-Model. 
Image generated using PYMOL.  C) 
Superimposition of wild type human α-Gal (1) 
with the projected structure of the mutant 
F273G/W277G form PHYRE.   
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Third Glycosylation Site Mutants 
 The human α-Gal has three N-linked glycosylation sites per monomer (Figure 13).  Site 
three (N215), was shown to be the most important for retaining activity and stability of the 
enzyme (3).  Upon the subsequent determination of the crystal structure of the human α-Gal it 
was observed that there is a hydrophobic loop that extends from the active site (Y207) to the 
third glycosylation site (N215).  We hypothesize that the glycosylation is necessary at this site to 
shield this hydrophobic loop from the surrounding aqueous solution.  In order to develop a 
potentially glycosylation independent therapeutic that theoretically could decrease an immune 
response or increase blood brain barrier permeability (24), the hydrophobic loop was targeted for 
mutagenesis.  The basic local alignment search tool (BLAST) was used with the query listed 
below to identify any homologs that were not glycosylated in that region.  Danio rerio 
(Zebrafish) was identified as a potential candidate because it lacked glycosylation site 3, also 
contains hydrophilic residues near this region of the enzyme sequence, and it catalyzes the same 
catalytic reaction with the natural Gb3 substrate.  The residues Met208 (M208) and Phe211 
(F211) were selected for mutagenesis to the gene for the zebrafish enzyme because of their 
hydrophobicity.  Analysis of the three-dimensional structure of the human enzyme in comparison 
with the previously mentioned active site homologs also identified that the loop was much longer 
in the human enzyme.  The longer loop is much more surface exposed than in the homologs so it 
was hypothesized that deletions of the hydrophobic residues may stabilize the enzyme.  Both the 
Zebrafish and the deletion mutations described are summarized in Figure 13.  In order to remove 
the glycosylation site, N215 was mutated to a Gln to prevent the post translational addition of the 
carbohydrate because glycosylation is selective to only Asn, while retaining similar charge 
properties (3).  Upon analysis of the Met208Glu/Asn215Gln (M208E/N215Q) mutant a large 
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increase in activity was observed, but the enzyme was not very stable.  The single mutant M208E 
was generated including the glycosylation site to further investigate this increase in activity. 
 All of the mutants explored in this research were constructed with the wild type P. 
pastoris strain X-33.  This strain produces high mannose glycosylation that can vary in 
molecular weight from preparation to preparation and would potentially be antigenic in vivo.  To 
address this issue, human α-Gal was integrated into the humanized P. pastoris strain SuperMan5 
for further studies outside the scope of this research.  SuperMan5 is commercially available as 
GlycoSwitch (Biogrammatics) and contains three genetic manipulations that result in only 5 
mannose glycosylation(49).  The blue/white screen of the integration of the wild type and F273C 
α-Gal into the SuperMan5 strain are located in Figure 14C (Results).  Other than those indicated 
all other strains derive from X-33. 
  
 
198 IVY SCREWPLYMWP FQKPNYT 217 Human primary sequence 
    IVY SCREWPLYXXP XQKPNYT Three residues selected for deletion (X) 
116 IVY SCREWPLYEWQ HQQPDYE 135 Zebrafish (D. rerio)(red differ from 
human) 
Figure 13. Primary sequence alignment to identify sites for mutation near glycosylation consensus 
NYT (215-217). 
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Methods and Materials 
Site Directed Mutagenesis 
 All the previously mentioned mutants were constructed using New England Biolabs’ Q5 
Site Directed Mutagenesis PCR kit in a pPICZαA P. pastoris expression plasmid(32) using 
custom mutagenesis primers constructed by Invitrogen (Thermo Scientific).  All constructed 
mutants are listed in Table 8 located in the results section.  Once the plasmids were constructed 
they were transformed into E. coli chemically competent cells purchased from either New 
England Biolabs (C2978H) or Agilent (XL 10-Gold Ultra Competent) and selected for 25 µg/mL 
Zeocin resistance.  Selected transformed colonies were cultured and isolated using a GeneJet 
Plasmid Miniprep kit purchased from Thermo Scientific and were sequenced by Genewiz to 
identify the presence of the mutation.  Sequence and alignments to the wild type α-Gal cDNA as 
well as the translation of the nucleotides were evaluated using Serial Cloner. 
Construction and Screening of P. pastoris Strains 
 Once the mutant sequence had been confirmed, the plasmids were digested with PmeI 
and visualized on a 1% agarose gel.  The linear plasmid was then purified by either drop dialysis 
or a Gene Clean III purification kit and electroporated into electrocompenent X-33 P. pastoris 
(32).  The transformed strains were selected on 100 µg/mL Zeocin plates and all resultant 
transformants were patched on to increasing concentrations of Zeocin (500 and 1000 µg/mL) to 
identify the strains with the highest amount of vector integration into the AOX gene of the 
chromosome.  The higher the copy number of the integrated α-Gal genes the more α-Gal the 
strain will produce.  The highest copy number strains were then patched on a nitrocellulose 
membrane and cultured overnight on a YPD agarose plate, then transferred to a minimal 
methanol plate to turn on α-Gal expression utilizing the AOX promoter for an additional night.  
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The next day the membrane was incubated in a 100 mM sodium acetate buffer containing 1 
mg/mL X-Gal (diluted from 20 mg/mL dissolved in dimethyl sulfoxide) to determine if the 
enzyme was functional using a blue/white screen. 
Culturing P. pastoris in shake flasks and purification of human α-Gal 
 All mutant strains as well as the wild type were cultured as described in Chen et al (32).  
In order to most accurately determine the kinetics and ultimately the stability of the mutant 
enzymes, the mutants need to be pure.  The culture was harvested via centrifugation and 
diafiltrated using either a 50 kDa or a 10 kDa hollow fiber filter (Spectrum Labs), depending on 
the anticipated molecular weight, into 10 mM sodium phosphate buffer pH 6.5.  Two alternative 
methods for purifying α-Gal utilizing two chromatography columns have been explored.  Both 
methods utilize as the first column, the anion exchange Diethylaminoethyl cellulose (DEAE) 
resin (GE Healthcare) eluted in 10 mM sodium phosphate buffer pH 6.5 with a gradient of 
increasing sodium chloride concentration up to 1 M (50).  The first method explored pooled the 
elution tubes and dialyzed them into a 25 mM citrate-phosphate buffer pH 4.8 with 0.1 M 
sodium chloride and loaded it on an affinity immobilized-D-galactose gel column (Thio-Gal, 
Pierce No. 20372) column (30).  The pure protein was eluted utilizing a step elution into 25 mM 
citrate-phosphate buffer pH 5.5 with 0.1 M galactose and 0.1 M sodium chloride.  This method 
was effective but the recovery was very low because approximately 2/3 of the enzyme fails to 
bind to the column.  It is hypothesized that varying glycoforms resulting from production in P. 
pastoris bind to the resin with distinctly different affinities.  Another issue is the resin binds to 
the active site of the enzyme and was observed to destroy the activity of the active site mutants 
when applied.  For these reasons an alternative second column was investigated. 
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 The second method explored the α-Gal elution peak, pooled and dialyzed against 25 mM 
citrate-phosphate buffer pH 4, for the second sulphopropyl (SP) Sepharose column (GE 
Healthcare), a cation exchanged resin.  This process was developed based on the literature 
isoelectric point of human α-Gal 4.7 (51).  The benefits of this purification method are the speed 
at which purification can be accomplished as well as the reduction in cost as opposed to affinity 
chromatography methods.   This method successfully purified the active site mutant enzymes for 
which it was used by analytical analysis with sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  Human α-Gal produced in P. pastoris results in multiple 
glycoforms of varying numbers of mannoses, which results in multiple bands observed on an 
SDS-PAGE.  These bands have identified as α-Gal via western blot(30) as well digestion of 
glycosylation with Peptide-N-Glycosidase F resulting in a single band(32).  Three of the 
interface mutants F273C, F273C/N278C, and F273G/W277G were not successfully purified due 
to poor stability during purification attempts and F273G/W277G’s failure to bind DEAE 
columns. 
Kinetic analysis of α-Gal 
 Substrate saturation curves using MUG were evaluated in three replicates with substrate 
concentrations ranging from 0.1 mM to 2 mM using the continuous enzyme assay detailed in 
Section IV.  The Km, Vmax, kcat and the efficiency kcat/Km were determined using three methods: 
Lineweaver-Burke for Michaelis-Menten kinetic curves; Eadie for sigmoidal curves; and non-
linear regression for all using Sigma Plot and Prism. 
Thermostability evaluation of α-Gal 
 Each purified mutant was evaluated for thermostability by being incubated in a water 
bath at 50
o
C.  A sample was taken at varying time points and placed on ice, and all activities 
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were read using the continuous assay simultaneously in comparison to the initial activity prior to 
incubation.  The initial activity of each respective mutant was considered to be 100% activity, 
and the activity at each time point was divided by the initial activity to define the percent 
activity.  The incubation was carried out for two hours. 
Analysis of the dimeric properties of α-Gal 
 It was reported that mouse α-Gal is observed to have different quaternary structure at 
different pH and varying salt concentrations(52).  This experiment was performed with the 
human enzyme to evaluate if the same trends would be observed.  Wild type human α-Gal was 
evaluated using a Superdex G200 size exclusion column at pH 7.4, 6.5, and pH 5.4 in the 
presence and absence of 150 mM or 100 mM sodium chloride. 
Electrophoresis analysis  
 Briefly to perform an SDS-PAGE, protein samples were mixed with an equal volume of 
reducing sample buffer (Bio-Rad Laemmli sample buffer with 5% β-mercaptoethanol) and 
heated for 5 minutes at 95°C before loading on a Mini-Protean TGX Precast Gel 4–20% (w/v) 
(Bio-Rad No. 456-1094). The running buffer for the SDS-PAGE was 25 mM Tris, 192 mM 
glycine, and 0.1% SDS.  Bands were identified by Coomassie blue staining via the modified 
Fairbanks protocol(53).  Native PAGE followed a similar protocol as the SDS-PAGE, 
supplementing the denaturation process with native sample buffer (Bio-Rad) and the running 
buffer used was the same as the SDS-PAGE minus the addition of SDS, with or without 50 mM 
galactose.  The gels were stained utilizing identical procedures. 
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Culturing P. pastoris in a bioreactor and purification of select mutants 
 High-density production of human α-Gal from P. pastoris in a 7 L bioreactor was 
described previously(30).  The purification of the mutants was similar to the process for shake 
flask, except scaled up accordingly.  The differences of note are that prior to the diafiltration all 
post-centrifuged harvests where filtered through 0.2 µm hallow fiber filter (Spectrum Labs, No. 
M22M-300-01N), and the Y207W mutant was not pure after the SP column so it was purified 
further on a Superdex G200.  E203C/Y207W was successfully purified utilizing the two-column 
DEAE and SP purification as was the shake flasks.  
Enzyme activity and protein concentration analysis 
Activity of α-Gal was assayed using the synthetic substrate, MUG as described 
previously (32) with modifications to be performed in a microtiter plate. Enzyme activity is 
measured in units/ml where one unit is defined as the amount of enzyme required to convert 1 
nmole of MUG to MU in one hour at 37°C. An aliquot of 3 μl was added to 27 μl of 5 mM MUG 
in 100 mM sodium acetate buffer, pH 4.6. This mixture was incubated at 37°C, and 10 μl 
aliquots were taken at two time points; the second was twice the first, and added to 290 μl of 0.1 
M diethylamine in a microtiter plate to stop the reaction. The fluorescence of each sample was 
measured at an excitation wavelength of 365 nm and an emission wavelength of 465 nm using a 
Tecan Infinite F200 microtiter plate reader. A standard curve of 10 μl of 0 – 0.5 nmol MU 
dissolved in methanol in 290 μl of 0.1 M diethylamine was used to quantitate the fluorescence 
emitted.  Protein concentration was determined by measuring the absorbance at 280nm on A 
NanoDrop
TM
 2000/2000c and calculations of concentration were determined using the literature 
extinction coefficient of human α-Gal(54). 
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Galactose activity assays 
 The wild type and the W277C mutant were evaluated for changes in activity as a result of 
galactose.  Parallel continuous assays were performed in triplicate containing varying 
concentrations of galactose for both the wild type and the mutant.  The activity at 0.5 mM 
galactose was considered to be 100% activity, and the activity at each additional concentration of 
galactose was divided by the initial to define the percent activity. 
Results 
Blue/White Screen 
 The X-Gal blue/white screen images for all of the mutants are displayed in Figures 14-15 
and the results are summarized in Table 8.  The only interface mutants that appeared blue in the 
screen were W277C and F273C/N278C (very faint blue appeared much later).  All of the 
interface mutants were explored in shake flasks to observe if any activity could be detected in 
culture.  The only active site mutants that retained activity were E203C, Y207W, and 
E203C/Y207W.  Y207W appeared clearly blue in several hours, but E203C and E203C/Y207W 
turned blue given more time incubating (Figure 15).    The active site mutations (E203C, 
Y207W, and E203C/Y207W) giving a blue result, were analyzed further in shake flasks.  The 
only glycosylation mutants to lose activity were Trp209X/Asn215Gln (W209X/N215Q) and 
Phe211His/Asn215Gln (F211H/N215Q); Met208X/Asn215Gln (M208X/N215Q) retained very 
slight activity that was only observed after overnight incubation so none of these mutants were 
evaluated further.  All of the other third glycosylation site mutants were evaluated in shake 
flasks. 
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A)    Interface Mutants 
Mutation 
Chosen for 
purification 
Blue/White screen activity 
F273C yes 
 
W277C yes 
F273C/W277C no 
F273G/W277G yes 
F273C/N278C yes 
B)    Active Site Mutants 
Mutation 
Chosen for 
purification 
Blue/White screen activity 
Y207W yes 
 
 
 
E203C yes 
E203C/Y207W yes 
D170C no 
E203N no 
E203C/ W204C/P205X/ 
L206X/Y207W 
no 
E203C/ W204N/P205X/ 
L206X/Y207W 
no 
Figure 14.  Blue/White X-gal screen of interface and active site mutants.  A) First row of the image contains 
controls of wild type α-Gal and X-33.  Second row contains all of the interface mutants.  B) The first image 
contains the active site mutants E203C/W204N/X/X/Y207W, and E203C/W204C/X/X/Y207W from one 
plate.  The second contains E203N from another, and the last contains the remaining active site mutants.   
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A) 3
rd
 Glycosylation Site Mutants 
Mutation 
Chosen for 
purification 
Blue/White screen activity 
M208E/N215Q yes 
 
 
 
 
 
M208E/F211H/ 
N215Q yes 
F211H/N215Q no 
M208X/N215Q no 
W209X/N215Q no 
F211X/N215Q yes 
N215Q yes 
M208E yes 
 
B) ) humanized P. pastoris strain (SuperMan 5) 
A) Mutation 
Chosen for 
purification 
Blue/White screen activity 
Wild type future studies 
 
F273C no 
 
 
Figure 15. Blue/White X-Gal screen of A) glycosylation mutants. B) humanized P. pastoris strain 
(SuperMan 5) containing the wild type α-Gal and the F273C mutation. 
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Table 8.  All constructed mutants and results of blue/white screen. 
Mutation Location Blue/White screen activity 
Y207W 
Active site 
 
blue 
E203C light blue 
E203C/Y207W light blue 
D170C white 
E203N white 
E203C/W204C/P205X/L206X/Y207W white 
E203C/W204N/P205X/L206X/Y207W white 
F273C 
Interface 
 
white 
F273G N/A 
W277C blue 
W277G N/A 
F273C/W277C white 
F273G/W277G white 
F273C/N278C very faint blue 
M208E/N215Q 
Third Glycosylation Site 
 
blue 
M208E/F211H/N215Q blue 
F211H/N215Q white 
M208X/N215Q very faint blue 
W209X/N215Q white 
F211X/N215Q blue 
N215Q blue 
M208E 
Loop between the active 
site and the third 
glycosylation Site 
blue 
46 
 
Secondary screening of mutant enzyme produced in shake flasks 
Culturing and purification in shake flasks 
 Four shake flasks were cultured for seven to nine days and growth and α-Gal production 
were monitored daily via optical density absorbance at 600 nm and enzyme assay respectively.  
The growth and production curves for the wild type are displayed in Figure 16.  The time of 
culture was determined based off enzyme production, longer durations were used for less active 
strains.  The four flasks were harvested together and pooled for purification.  The SDS-PAGE 
results using both column purification techniques are represented in Figure 17, and the 
purification tables are shown in Tables 9 and 10. 
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Table 9. Wild type Purification Table 
Step 
Protein 
Concentration 
(mg/mL) 
Enzyme 
Activity 
(units/mL) 
Specific 
Activity 
(units/mg) 
Fold 
Purification %Yield 
Supernatant 0.714 9,315 13,046 1.00 100% 
DEAE 0.15 8,040 53,600 4.11 80% 
Thio-gal 0.03 15,225 507,500 38.9 20% 
Table 10. E203C/Y207W Purification Table 
Step 
Protein 
Concentration 
(mg/mL) 
Enzyme 
Activity 
(units/mL) 
Specific 
Activity 
(units/mg) 
Fold 
Purification %Yield 
Supernatant 1.450 4,545 3,134 1.00 100% 
DEAE 0.361 6,450 17,867 5.70 85% 
SP 0.023 2,276 98,935 31.6 10% 
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Figure 16.  A) Growth of P. pastoris in shake flasks monitored by optical density.  B) Production of 
wild type α-Gal in shake flasks.  The four curves represent individual cultures in parallel. 
  
 Figure 17. SDS-PAGE of wild type α-Gal purification with DEAE and Thio-gal (left).   SDS-PAGE of 
E203C/Y207W α-Gal purification with DEAE and SP (right).  71.1 is the harvest, 71.2 is diafiltrated 
sample, 71.4 is the DEAE pool, and 71.7 is the concentrated SP pool. 
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Comparison of the kinetics of α-Gal mutants 
 The kinetic results for the purification from shake flasks of all mutants are summarized in 
the appendix (Tables 26 and 27).  Tables 11 and 12 highlight the kinetics of the mutants that 
were stable enough to undergo purification.  There were two different continuous assays used to 
generate this data one with an excitation at 360 nm and emission at 465 nm and the other at 315 
nm and emission at 450 nm.  See Chapter 4 on the details of these assays.  Due to the fact that 
the two assays do not provide comparable data to each other and kinetics are most accurate 
before freezing, Tables 11 and 12 represent the most accurate data for each mutant.  Most of the 
mutants’ relative efficiency (kcat/Km) was less than the wild type irrespective of the assay used.  
However, three mutants showed an increase in efficiency: Y207W; M208E/N215Q; and 
F211X/N215Q.  Y207W is the single active site mutation that was observed in C. josuil, S. 
cerevisiae, and P. chrysosporium.  This residue does not bind to the substrate according to the 
catalytic mechanism(1), but it is involved in the stabilization by hydrogen bonding of the 
hydroxyl of the Tyr to the carbonyl of D170, which is the residue that initiates catalysis by its 
nucleophilic attack on the anomeric carbon of the galactose.  We hypothesize that the mutation 
of this residue to a Trp prevents this hydrogen binding stabilization, increasing the reactivity of 
D170, which is observed in the greater than 2-fold increase in Vmax.  The Km is slightly decreased 
(less than 2-fold) as well, which could be explained as a byproduct of the change in equilibrium 
of the reaction with the increase in catalysis. 
 Mutants M208E/N215Q and F211X/N215Q are both third site glycosylation knockouts 
with the additional modification to the hydrophobic loop.  The M208E allele is the residue next 
to the active site in the primary sequence but in three-dimensional space, the R group faces away 
from the active site residue Y207, due to the trans nature of peptide bonds.  The stability of this 
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sample was impaired, making it unable to be tested using the new continuous assay, so it seems 
that the increase in kinetic efficiency is more of an unexpected effect of catalysis than stability.  
One possible explanation is the mutation to a hydrophilic residue allows for more water 
molecules to be available for the second substrate in the catalytic mechanism.  Further study was 
done for the M208E mutation with the glycosylation intact, and that mutant was cultured in the 
bioreactor directly.  F211X is possibly increasing activity with a similar mechanism as the 
M208E mutation, but since the residue is further from the active site, the change is less drastic, 
which might explain the increase in Vmax observed with no change to the Km.  The Y207W, 
M208E, E203C/Y207W, and W277C mutants were scaled up to the bioreactor for further 
analysis.  M208E/N215Q and F211X/N215Q were not scaled up due to the observed decrease in 
stability. 
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Table 11. Non-linear regression of mutants assayed at an excitation of 315 nm 
Location of 
Mutation 
Mutation 
Km           
(mM) 
Vmax 
(mmol/hr/mg) 
kcat              
(s
-1
) 
kcat/Km   
(M
-1
s
-1
) * 10
3 
Relative 
kcat/Km  
to WT 
N/A 
Wild 
type 
1.10 ±0.06 0.067 ± 0.0029 1.68 ± 0.07 1.52 ± 0.03 1.00 
Active Site 
E203C 1.68 ± 0.25 0.041 ± 0.0048 1.01 ± 0.12 6.04 ± 17 0.399 
Y207W 0.62 ± .08 0.177 ± 0.0077 2.93 ± 0.19 4.75 ± 0.28 3.11 
E203C/ 
Y207W 
1.02 ± 0.11 0.045 ± 0.0017 1.12 ± 0.04 1.10 ± 0.07 0.84 
Glycosylation 
F211X/ 
N215Q 
0.98 ± 0.12 0.207 ± 0.0123 5.18 ± 0.31 5.33 ± 0.36 3.50 
M208E/ 
F211H/ 
N215Q 
1.51 ± 0.62 0.045 ± 0.0147 1.12 ± 0.32 0.756 ± 0.06 0.50 
N215Q 1.28 ± 0.15 0.019 ± 0.0011 0.48 ± 0.03 0.380 ± 0.22 0.25 
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Table 12. Non-linear regression of mutants assayed at an excitation of 360 nm 
Location of 
Mutation 
Mutation 
Km           
(mM) 
Vmax 
(mmol/hr/mg) 
kcat              
(s
-1
) 
kcat/Km   
(M
-1
s
-1
) * 
10
3
 
Relative 
kcat/Km  
to WT 
N/A 
Wild 
type 
0.668 
±0.026 
0.028 ± 0.0004 
0.71 ± 
0.01 
1.06 ± 0.03 1.00 
Interface W277C 0.56 ± 0.04 0.018 ± 0.0008 
0.45 ± 
0.02 
0.80 ± 0.02 0.746 
Glycosylation 
M208E/ 
N215Q 
0.46 ± 0.05 0.11 ± 0.0015 
2.75 ± 
0.04 
5.98 ± 0.58 5.62 
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Quaternary structure of α-Gal 
 There was no change in molecular weight of the wild type enzyme observed under any of 
buffer conditions investigated; only the two overlapping peaks of dimer were observed.  The 
peaks are consistent with the multiple molecular weights observed on the SDS-PAGE resulting 
from multiple glycoforms of the wild type enzyme produced in P. pastoris. Only one of the 
interface mutants was successfully purified from the shake flasks (W277C), and this mutant was 
analyzed under the same condition as the wild type.  The majority of protein in the W277C 
sample was an aggregated high molecular weight species, consistent with an octamer, with a 
minor peak being the dimer as observed in Table 13.   
Table 13. Molecular weights of purified enzymes. 
 
 
 
Thermostability analysis  
 Initially all successfully purified mutants from shake flasks with the exception of 
M208E/N215Q were analyzed for their relative thermostabilities in comparison to the wild type 
using the continuous assay at 42
o
C.  M208E/N215Q was excluded because it was so unstable it 
did not survive freeze thaw.  The goal was to observe, in real time, the denaturation of each 
mutant by observing a plateau or a decline in the fluorescence of MU the product over time 
(Figure 18).  Unfortunately, this inflection or plateau was difficult to determine experimentally, 
and an alternative assay was developed that is described in the methods section. 
Major peak Minor peak
Wildtype 126-106 -
W277C 511-364 85
Sample
Molecular Weight (kDa)
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 The data obtained for the water bath stability analysis of the purified mutants from shake 
flasks is presented in Figure 19.  With the exception of N215Q all glycosylation mutants were 
not evaluated for thermostability because they lost activity prior to the second stability analysis.  
This experiment however, is not a completely valid comparison of each mutants’ stability 
because there are other variables that may confound the results.  The mutants were not all in the 
same buffer, so there is a variation in pH as well as conductivity, and the concentrations of the 
enzymes were not standardized.  It has been observed in this lab that wild type α-Gal increases in 
stability with greater concentration.  The summary of these differences is displayed in Table 14.  
Despite these confounding variables, there is one significant observation to emphasize, W277C 
(interface mutant) is remarkably stable.  The concentration of W277C is comparable to E203C 
(active site mutant), and the buffers are the same, yet after two hours at 50
o
C E203C had lost all 
of its activity whereas W277C retained 50% activity.  There is little reason to suspect that the 
difference in stability observed between E203C and the wild type is more than just the 10 fold 
difference in the concentration of enzyme, because a mutation within the active site pocket is not 
likely to affect stability.  Due to this observed increase in stability W277C was cultured in the 
bioreactor for further study. 
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Figure 19. Comparison of the thermostability of the mutants to the wild type prepared from 
shake flasks observed as percent initial activity over time.  The wild type and E203C/Y207W 
overlap with N215Q. 
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Figure 18. Comparison of the thermostablity of the mutants to the wild type prepared form 
shake flasks as observed as fluorescence over time. 
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Table 14. Variables in shake flasks thermostability analysis. 
Mutant 
Concentration of 
Enzyme (mg/mL) 
Buffer 
WT 0.006 10 mM Sodium Phosphate pH 6.5 
W277C 0.063 10 mM Sodium Phosphate pH 6.5 
E203C 0.077 10 mM Sodium Phosphate pH 6.5 
Y207W 0.014 10 mM Sodium Phosphate pH 6.5 
E203C/Y207W 0.023 
25 mM Citrate- Phosphate pH 4 
250 mM Sodium Chloride 
N215Q 0.035 
25 mM Citrate- Phosphate pH 4 
250 mM Sodium Chloride 
  
 
. Comparison of the thermostability of the mutants to the wild type prepared from shake flasks observed as a change in 
fluorescence of MU per mg of enzyme over time. 
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In depth analysis of mutants expressed in a bioreactor  
Production and purification of enzymes in a bioreactor 
 The process of producing α-Gal in a bioreactor has been developed in this lab (30).  
Culturing in the bioreactor allows for greater control over variables such as pH, dissolved 
oxygen, and temperature, which elevates the production of enzyme as well as increases the 
volume of culture.  The growth, measured by wet weight, and the production of α-Gal, measured 
by enzyme assay, for the wild type is shown in Figure 20.  Wild type enzyme was produced and 
purified using DEAE and Thio-gal in order to compare the kinetics using the new continuous 
assay to the most efficient mutants identified (Y207W, M208E, E203C/Y207W, W277C) and to 
the published values.  The active site mutants were purified with an SP column as a second 
column, and Y207W required an additional step of using a Superdex G200 (GE healthcare).  The 
W277C and M208E mutants were purified with the Thio-gal column as the second column.  The 
SDS-PAGE analyses for each purification are located in Figures 21-23, and the purification 
tables are summarized in Tables 15-18. 
 Figure 20. Wild type α-Gal production in a bioreactor.  The black line is the wet weight readings and 
the brown line is the activity of α-Gal. 
Wet Weight 
Activity 
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A)  SDS-PAGE of WT α-Gal 
 
B)  Purification table for WT α-Gal 
Aliquot Step 
Protein 
Concentration 
(mg/mL) 
Enzyme 
Activity 
(units/mL) 
Specific 
Activity 
(units/mg) 
Fold 
Purification 
%Yield 
77.1 Supernatant 6.046 19,388 3,207 1.00 100% 
77.2 Diafiltration 3.404 104,175 30,604 9.54 67% 
77.5 DEAE 0.634 125,850 198,502 61.90 41% 
77.10 Thio-gal 0.001 4,598 4,597,500 1,434 1% 
 
 
 
Figure 21. A) SDS-PAGE of purification 77 is the wild type. B) The purification table identifies 
the sample in each lane. 
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Table 16. W277C Purification Table 
Aliquot Step 
Protein 
Concentration 
(mg/mL) 
Enzyme 
Activity 
(units/mL) 
Specific 
Activity 
(units/mg) 
Fold 
Purification %Yield 
80.1 Supernatant 3.023 2,880 953 1.00 100% 
80.2 Diafiltration 0.9 9,263 10,212 10.7 75% 
Table 15. E203C/Y207W Purification Table 
Aliquot Step 
Protein 
Concentration 
(mg/mL) 
Enzyme 
Activity 
(units/mL) 
Specific 
Activity 
(units/mg) 
Fold 
Purification %Yield 
79.1 Supernatant 4.04 1,715 425 1.00 100% 
79.2 Diafiltration 4.06 9,188 2,263 5.33 67% 
79.23 DEAE 0.353 5,123 14,511 34.18 1.9% 
79.24 SP 0.005 2,418 483,600 1,139 0.4% 
 
Figure 22. SDS-PAGE of purification 79 is the E203C/Y207W mutant 
(Table 14) and 80 is the W277C mutant (Table 15). The purification 
table identifies the sample in each lane. 
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80.6 DEAE 0.396 5,655 14,280 15.0 20% 
80.11 Thio-gal 0.004 29,363 7,340,625 7,705 5% 
 
 
 
 
Table 17. Y207W Purification Table 
Aliquot Step 
Protein 
Concentration 
(mg/mL) 
Enzyme 
Activity 
(units/mL) 
Specific 
Activity 
(units/mg) 
Fold 
Purification %Yield 
81.1 Supernatant 4.159 2,925 703 1.00 100% 
81.2 Diafiltration 1.0 3,664 3,735 5.31 50% 
81.6 DEAE 0.195 10,035 51,462 73.2 69% 
81.7 SP 0.016 923 57,656 82 0.09% 
81.15 SEC 0.0004 360 898,750 1,278 0.02% 
 
 
Figure 23. SDS-PAGE of purification 81 is the Y207W mutant (Table 
16) and 82 is the M208E mutant (Table 17). The purification table 
identifies the sample in each lane.  
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Table 18. M208E Purification Table 
Aliquot Step 
Protein 
Concentration 
(mg/mL) 
Enzyme 
Activity 
(units/mL) 
Specific 
Activity 
(units/mg) 
Fold 
Purification %Yield 
82.1 Supernatant 4.043 46,650 11,538 1.00 100% 
82.2 Diafiltration 0.9 304,500 344,847 29.9 135% 
82.6 DEAE 0.632 171,300 271,044 23.5 46% 
82.8 Thio-gal 0.012 101,250 8,437,500 731.3 1% 
 Purified α-Gal from P. pastoris often exists in multiple glycoforms and can appear as 
multiple bands on an SDS-PAGE.  These bands have been previously identified as α-Gal by 
western blot(30) and by digestion with Peptide-N-Glycosidase F (9).  In the case of the Y207W 
mutant (81.15), there were some difficulties during the purification.  Although a band is not 
visible in this image, it was visible with the eye and slightly more apparent on a native gel in 
Figure 28 (Quaternary structure section). Due to the issues in purification and the extremely low 
concentration the Y207W mutant likely lost a large amount of activity, and therefore the 
subsequent characterization experiments may be a bit misleading.  The low yields in many of the 
cases are the result of a separation of the pool at key steps to serve as a back-up.  This result was 
especially necessary for the SP purified mutants because of the need to trouble shoot the scale up 
to the bioreactor.  In the case of the mutants purified using Thio-gal chromatography, the 
majority of the enzyme consistently fails to bind the resin, independent of the amount loaded.  
We hypothesize that the different glycoforms bind with varying affinities, which was observed 
with the purification of the third glycosylation site knockouts from the shake flasks having a 
much better binding capacity. 
Kinetic analysis of mutants purified from the bioreactor 
 The kinetic analysis of the mutants purified from bioreactors rendered different results 
than was observed in the shake flasks, not only in the quantitation of the Vmax or Kcat but the 
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relative efficiency was not always consistent with the shake flask data.  The kinetic results of the 
wild type to validate the change in assay from the time point assay to the continuous assay for 
detection are summarized in Table 19.  Details on the assay are described in the next chapter.  
The summarized results of the non-linear regression analysis for all mutants are located in Table 
20.  Two of the mutants explored, W277C and M208E appeared to deviate from the expected 
Michaelis-Menten rectangular hyperbola and were sigmoidal consistent with positive 
cooperativity.  The substrate saturation curves and Eadie plots are displayed in Figure 24 for the 
wild type, W277C, and M208E.  W277C displayed a Hill coefficient (coefficient to determine 
degree of cooperativity) of 4.6 ± 0.99, which is inconsistent with a dimeric species, so further 
experiments were used to characterize this mutant in particular.  M208E is less sigmoidal with a 
Hill coefficient of 3.47 ± 1.36, but is not consistent with only two binding active sites.  It was 
previously observed in the crystal structure of α-Gal that there is a secondary binding site per 
monomer that binds β-D-galactose as opposed to α-D-galactose, which is bound by the active 
site and is a known competitive inhibitor.  The authors of the paper other than identifying the site 
have not determined the site’s function in the wild type (55).  It was hypothesized that this 
secondary site might be involved in some allosteric effect that is more pronounced in the 
mutants, and this hypothesis was explored further.  There is no evidence for any cooperative 
binding of MUG to wild type α-Gal in the literature or observed in this lab, however there is 
report of a Hill coefficient of 1.9 of the natural substrate, Gb3, to the wild type enzyme, 
identifying a precedent of positive cooperativity(56). 
 These two mutants were the only observed to increase the relative efficiency of catalysis 
2 to 3-fold.  M208E increased the Vmax of the enzyme with little observed change to the Km or 
K0.5, since the curve does not fit a Michaelis-Menten prediction.  This result is consistent with 
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the initial hypothesis that mutation to a hydrophilic residue increases the availability of water for 
catalysis.  W277C decreased the Km or K0.5 with little observed improvement to the Vmax.  Since 
this mutation is located in the interface with an extremely high Hill coefficient, the cooperativity 
between the subunits is likely affecting the binding of the substrate. 
 Both active site mutants (Y207W and E203C/Y207W) appear to decrease the efficiency 
of the enzyme, and in the case of Y207W, that is inconsistent with the shake flask result.  Since 
this mutant was unable to be purified the same way from shake flask to bioreactor the issue 
might be a result of the third column drastically diluting the enzyme and compromising the 
stability. This stability issue would explain the decrease in the Vmax observed, but it is possible 
that the bioreactor is the true result.  There is enough ambiguity to this mutant’s result to warrant 
further investigation as well as the development of an optimized purification procedure. The Km 
observed is consistent in being lower than the wild type to the shake flask result.  However, if 
this result is confirmed through further testing, the initial hypothesis does not hold up because 
the Vmax is less than the wild type.  In the event that the purification is optimized and the stability 
is maintained there is reason to believe that the shake flask trend may be confirmed.  The trend 
for E203C/Y207W is fairly consistent between the shake flasks and the bioreactor.  Both result 
in a decrease in relative efficiency, with no significant change to the Km, but a decrease in the 
Vmax.  The only difference of note is the degree of the decrease observed between the bioreactor 
and the shake flasks.  The shake flasks observe a twofold decrease, whereas the bioreactor 
demonstrates a fourfold decrease.  It is important to clarify that the quantification of the Vmax is 
always significantly lower in the shake flasks than in the bioreactor, so that very well could 
explain the discrepancy.  The difference between 0.045 and 0.067, observed in the shake flasks 
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of E203C/Y207W and the wild type respectively, and 0.43 and 2.25, detected in the bioreactor 
could just be a side effect of the increase in magnitude. 
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Table 19. Comparison of kinetic parameters of wild type enzyme purified from a 
bioreactor using the time point and the new continuous assay 
Assay 
Excitation 
Emission 
Km 
(mM) 
Vmax 
(mmol/hr/mg) Kcat (s
-1
) Km/Kcat (M
-1
 s
-1
) 
Time 
point(30) 
360nm 
465nm 
2.44 ± 
0.44 
3.36 ± 0.25 84 34,400 
Continuous 
Lineweaver-
Burke 
315 nm 
450nm 
2.14 ± 
0.07 
2.96 ± 0.183 74.1 ± 4.58 34,026 ± 982 
Continuous 
Non-Linear 
Regression 
315 nm 
450nm 
1.48 ± 
0.09 
2.25 ± 0.141 56.2 ± 3.53 38,026 ± 447 
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Table 20. Comparison of kinetic parameters of wild type enzyme to all mutants purified from a 
bioreactor using the new continuous assay and non-linear regression with Prism 
Mutant 
Km or K0.5        
(mM) 
Vmax 
(mmol/hr/mg) 
Kcat (s
-1
) 
kcat/Km  
(s
-1
 M
-1
) 
Hill 
coefficient 
Relative 
Kcat/Km 
Wild type 
1.48 ± 0.09 2.25 ± 0.14 56.2 ± 3.53 38,026 ± 447 1.00 1.00 
E203C/Y207W 
Active Site 2.09 ± 0.72 0.43 ± 0.12 10.7 ± 3.09 5,203 ± 281 1.00 0.14 
Y207W     
Active Site 1.10 ± 0.02 0.76 ± 0.03 19.1 ± 0.72 17,309 ± 408 1.00 0.46 
W277C  
Interface 0.70 ± 0.05 2.46 ± 0.19 61.4 ± 4.85 87,809 ± 8,169 4.60 ± 0.99 2.31 
M208E       
Loop 1.12 ± 0.33 5.08 ± 1.44 127 ± 35.9 114,431 ± 3,439 3.47 ± 1.36 3.01 
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Figure 24. Subrate saturation data (a) and an Eadie plot (b) for the wild type in comparison to the 
mutants M208E (c and d) and W277C (e and f). 
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Quaternary structure of α-Gal and effect of galactose 
 The initial shake flask high molecular weight and the high Hill coefficient observed for 
W277C indicated that the quaternary structure of the bioreactor sample should be investigated 
further.  When the same size exclusion chromatography experiment was repeated with the 
W277C mutant purified from the bioreactor the shake flask potential octameric result was not 
reproduced.  In that experiment, the molecular weight of W277C was calculated to be 108.3 kDa, 
consistent with a dimeric species, in a sharp single peak of only one observed glycoform (Figure 
25).  The observed dimer was unexpected for W277C, given the high Hill coefficient observed.  
Upon further analysis of the predicted structure of the monomer of W277C, generated by 
PHYRE, in comparison to the crystal structure of the wild type(4) (PDB code 3HG2) containing 
the secondary binding site in PyMOL, there was a perceived structural change to the secondary 
binding site.  This site has been reported to selectively bind β-D-galactose; however the 
predicted structure of W277C resulted in a change in positioning of the side chain of the 
glutamine (Gln250) in that secondary site.  The amide of this glutamine is in the location of the 
anomeric carbon of the galactose giving more room for an axial hydroxyl, α-D-galactose, as 
opposed to selecting exclusively for a β-D-galactose.  Figure 26 depicts the binding of the 
galactose in the wild type, illustrating the location of the glutamine. 
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 This observation, lead to the hypothesis that this secondary site was causing galactose to 
act as an allosteric activator in the mutant.  To test this hypothesis, the wild type and the mutant 
were analyzed side by side in the presence of varying concentrations of galactose.  There 
appeared to be no difference between the two in terms of activity.  Galactose appears to be solely 
an inhibitor for both (Figure 27) with an inhibitor concentration of 50% (IC50) of approximately 
10 mM for both. 
  
 
Figure 25. Size exclusion chromatography A280 profile of the purified wild type enzyme (left) and the 
purified W277C mutant (right) produced in bioreactors and analysis carried out in 10 mM sodium 
phosphate buffer pH 6.5 and 100 mM sodium chloride. 
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Figure 26. Effect of galactose on activity A) %Activity versus concentration 
of galactose.  B) Inhibitor Concentration 50% graph, %Activity versus log10 
galactose 
Figure 27. β-D-galactose bound to secondary site in the wild 
type (PDB 3HG2(4)).  Image generated in PyMOL. The amide 
of Gln250 is depicted in blue. 
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 Although the structure appeared to be a dimer in on the size exclusion chromatography, 
this was determined in the absence of galactose.  Despite the fact that galactose was shown to not 
be an activator of W277C, this does not preclude a difference in the structure of the mutant to the 
binding of galactose, which could explain the sigmoidal curve observed.  It has been previously 
observed in the literature that galactose can act as a molecular chaperone and affect the folding 
mutant enzymes associated with disease as well increase the thermostability of the wild type 
enzyme (57).  We hypothesized that the mutant would undergo a structural change in the 
presence of galactose, which we evaluated by native gel in the presence and absence of galactose 
compared to the wild type as well as the M208E mutant.  The native PAGE with galactose and 
without galactose showed a retarded migration of W277C compared to the wild type, Y207W, 
and M208E (Figure 28).  This indicates that the change in structure is independent of galactose 
presence. 
  
                                
Figure 28. Native gel of mutants in the presence of 50 mM galactose (left) and in the 
absence of galactose (right). 
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Thermostability 
 The stability analysis of the purified bioreactor samples was tested using the same 
method as the shake flasks; to mitigate the differences in concentration and buffer, all the 
samples were concentrated using an Amicon centrifuge filter (Millipore) and buffer exchanged 
into 25 mM citrate-phosphate buffer pH 4.  Figure 29 depicts the relative thermostabilities of all 
of the purified mutants from bioreactors with the exception of Y207W.  The concentration of the 
Y207W mutant was too low in comparison to the other samples for a fair comparison.  The final 
concentrations for all of the stability samples were diluted down to 0.006 mg/mL, which was the 
concentration for the wild type in the shake flask stability experiment.  The stabilities are more 
or less the same for all of the mutants and the wild type in a standardized buffer and 
concentration.  The W277C enzyme appears slightly more stable than the rest at 20% activity at 
15 min as opposed to approximately 10% for the other samples, but in the absence of replicates 
there is no assurance in the significance of that observation.  The difference between the stability 
observed for W277C in the shake flasks and the bioreactor is likely a factor of the tenfold 
difference in concentration. 
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Figure 29. Comparison of the thermostability of the mutants to the wild type 
prepared from bioreactors observed as percent initial activity over time. 
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Discussion 
 Mutations were constructed in an attempt to increase catalysis, increase stability, and to 
test the theory that the enzyme might become glycosylation independent.  The active site was 
targeted to increase the activity of the enzyme using homology modeling as well as organic 
chemistry principle design.  Seven active site mutants were constructed of which three retained 
activity and four did not.  Of the four that lost activity, Glu203Asn (E203N), 
E203C/W204C/P205X/L206X/Y207W, and E203C/W204N/P205X/L206X/Y207W were 
constructed based on homology modeling.  We hypothesize that E203N lost activity because the 
amide group was unable to hydrogen bind to the galactose, which rendered the enzyme unable to 
bind the substrate.  In the E203C/W204C/P205X/L206X/Y207W and 
E203C/W204N/P205X/L206X/Y207W mutants it is possible that in the human enzyme the 
residues were too close to each other to correctly promote catalysis.  Since the E203C/Y207W 
enzyme retained activity at a distance of three residues in an α-helix as opposed to one residue in 
a predicted loop, it was not the cause for the loss of catalysis observed.  In the case of D170C it 
is possible that either the thiol did not act as a nucleophile because it was perhaps too far away 
from the anomeric carbon or it reacted but failed to release the galactose product resulting in 
irreversible inhibition. 
 The interface was targeted for mutation in the intention of increasing the stability of the 
enzyme while not decreasing the catalysis.  Mutants F273C/W277C and F273C/N278C were 
constructed in an attempt to stabilize the dimer using two disulfide bonds across the interface 
rather than aromatic stacking.  The blue/white screen indicted that even if the disulfide bond was 
formed the activity was severely compromised.  The F273G/W277G mutant was constructed 
because it was previously reported to be an active monomer (48).  A monomeric form of α-Gal 
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would be therapeutically useful because smaller molecules are able to be taken up into podocytes 
better, which is a primary accumulation site of substrate in Fabry disease.  The blue/white screen 
indicted that if the mutant formed a monomer the activity was severely compromised to the point 
it was undetectable.  F273C and W277C were constructed to stabilize the dimer using 
thiol/aromatic interactions.  F273C was completely inactive whereas W277C retained decent 
activity.   We hypothesize that F273’s location on a loop as opposed to W277’s location on an α-
helix allowed for greater flexibility for the thiol/aromatic interaction between the π electrons of 
the phenyl ring of F273 and the thiol of W277C, than an interaction between the π electrons of 
the indole ring of W277 and the thiol of F273C. 
 The last target for mutation was the hydrophobic loop between the active site and the 
third glycosylation site N215 in an attempt to construct a glycosylation independent enzyme.  
The glycosylation was removed by a mutation of N215Q, so all subsequent mutants were at least 
double mutations containing this mutation.  Two approaches were utilized to mitigate this 
hydrophobic patch: one was introducing substitutions based on the primary sequence of the 
Zebrafish which does not have a glycosylation site at that region; the second was deletion of the 
hydrophobic residues shortening the loop.  Most of these mutants retained activity; the only two 
that completely eliminated activity were F211H/N215Q, from the Zebrafish, and the deletion 
W209X/N215Q.  Interestingly the triple mutant M208E/F211H/N215Q retained activity, but the 
activity was lower than the M208E/N215Q indicating that the F211H mutation decreases activity 
but that an additional hydrophilic residue can overcome it.  The predicted structure of the F211H 
mutation depicts the His side chain in close proximity to the Met side chain, which could explain 
this observation.  The predicted structure of the W209X/N215Q mutant projects that the deletion 
of the Trp results in a complete disruption of the α-helix in the active site, which would explain 
76 
 
the loss of activity.  The M208X/N215Q allele severely decreased the activity observed but some 
was retained.  The large increase in activity observed in the M208E/N215Q, lead us to 
hypothesize that this was a result of an increase in catalysis not stability.  The M208E allele was 
constructed containing the glycosylation site to further investigate this, and high activity was 
observed. 
 The use of a screening procedure involving an initial production and screening in shake 
flasks is an effective tool for determining which mutants are appropriate for further study.  
However, the results gathered should not be considered definitive, as these results have shown.  
There are significant discrepancies observed between the shake flasks results and the bioreactor 
results as to quantification, yet there appeared to be a trend.  The interface mutant, W277C, was 
determined to be positively cooperative and more active in the bioreactor.  In the shake flasks the 
sigmoidal curve was extremely slight and was only noticed after the results for bioreactor were 
obtained, however on re-examination and curve fitting with a sigmoidal function the Km/K0.5 was 
determined to consistent with the bioreactor results.  The Hill coefficient from the shake flask 
data was significantly less, 1.32±0.24, than the bioreactor result of 4.60±0.99, but the shake flask 
result is more consistent with a dimeric species. 
 Further analysis needs to be done to explain the extreme positive cooperativity observed 
in this mutant that deviates from the literature which states that the Hill coefficient should not 
exceed the number of binding sites (58).  The size exclusion chromatography has determined the 
structure to be dimeric; the native PAGE identifies a slightly retarded migration however, that is 
observed with or without galactose, which does not contradict the size exclusion result.  Since 
the migration on the SDS-PAGE is the same as the wild type the best interpretation of all of 
these results that W277C causes a significant conformation change (native PAGE) but is still a 
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dimeric species.  The significant change in conformation is most plausible since the mutation 
occurs at the dimer interface.  The substitution of a tryptophan to a cysteine can very well cause 
shifting of the axis of the association of the two monomers, which can be causing the 
cooperativity observed.  This explanation is entirely theoretical in the absence of a crystal 
structure or a model to predict quaternary structure with any accuracy. 
 The inhibition observed with galactose was indistinguishable from the wild type 
indicating that galactose is not binding and activating the mutant at the secondary site.  There 
have been reports that the E. coli enzyme threonine deaminase varies in Hill coefficient 
depending on the binding of different compounds to the enzyme such as valine (1.0), isoleucine 
(3.9), or the absence of effectors (2.3) (59). One possible explanation in regards to this 
phenomenon is that the substrate, itself is binding to the secondary site and activating the 
catalysis, however many more studies would be needed to determine that.  The possible increase 
in stability observed in this mutant should be further investigated as well. 
 The results for the M208E mutant cannot be directly compared to the shake flask results 
of M208E/N215Q, but the stability being comparable to the wild type can be explained by the 
retention of the glycosylation.  The relative increase in catalysis observed being consistent with 
both mutants gives more support to the initial hypothesis that the increase in activity observed 
was independent of the glycosylation and an unexpected effect on the active site.  The presence 
of a hydrophilic residue, glutamate, adjacent to the active site as opposed to a highly 
hydrophobic residue, methionine, may increase the water molecules available to bind as the 
second substrate in the ping-pong bi-bi reaction (1) which in turn increases the rate of catalysis 
(Vmax).  There is a slight improvement in the Km or K0.5, but the more interesting phenomenon is 
the appearance of positive cooperativity in this mutant as well.  The Hill coefficient for this 
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mutant is 3.47±1.36, which is higher than would be expected for a dimer; however in light of the 
large standard deviation it is not necessarily so large that it is unbelievable.  The Native PAGE 
indicates that the quaternary structure of M208E is similar to the wild type, and unlike W277C; 
there is no reason to believe that there is a large confirmation change.  In light of the previous 
observation of the wild type enzyme undergoes positive cooperativity with Gb3 but doesn’t with 
MUG (7).  It is possible that this mutation exacerbates the unknown mechanism that result in the 
substrate distinction. 
 The most obvious inconsistency between the bioreactor results and the shake flask results 
is shown in Y207W.  The shake flasks identified a 3-fold increase in efficiency as compared to 
the wild type, with improvement in both Vmax and Km, yet the bioreactor showed a 2-fold 
decrease in efficiency retaining the improvement to Km but resulting in a 3-fold decrease in Vmax.  
Although this is a concerning discrepancy, it is at the same time misleading.  Although the 
Y207W mutant was successfully purified with DEAE and SP in shake flasks it was unable to be 
purified utilizing the same method from the bioreactor.  Additionally confounding is the 
observation that E203C/Y207W was successfully purified using that method in both.  Y207W 
could not be purified on Thio-gal because loading the enzyme on the column on multiple 
occasions resulted in complete inactivation of the enzyme.  We hypothesized that this was 
because α-Gal binds Thio-gal at the active site, which is the location of the Y207W mutation.  
Due to the substantial difficulties purifying this particular mutant, it is reasonable to be skeptical 
of the decrease in Vmax observed.  Had the enzyme only gone through a two-column purification 
like the others and resulted in more concentrated enzyme; it would be a more valid comparison.  
For this reason it may be worth developing a more optimal purification procedure for this mutant 
in the future. 
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 The results from the shake flasks and the bioreactor are consistent for the E203C/Y207W 
mutant.  Both methods determined that this mutation resulted in a decrease in efficiency in 
comparison to the wild type particularly in regards to catalysis (Vmax).  The reason this mutant 
was selected for study in the bioreactor was to better characterize the difference between the 
double mutant and the single mutant Y207W.  Due to the issues previously mentioned with 
Y207W this analysis has not been fully carried out and should be looked into in the future. 
 From a therapeutic perspective, the best candidates put forward from this research are 
W277C and M208E.  Y207W upon optimization may also prove to be a likely option as well.  
The threefold increase in catalysis observed with M208E may result in a lower dose necessary 
for patients.  The twofold increase in catalysis observed with W277C as well as the potential 
increase in stability may result in a lower dose or a longer time between infusions for patients.  
Lower dosage would in turn decrease the immune response experienced by patients (21).  
Another mutation that may be worth looking into would be a glycosylation intact F211X.  It 
would be interesting to investigate if the increase in catalysis observed in the shake flasks was 
due to that mutation or the elimination of a potentially hindering carbohydrate chain.  
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 : Development of a Continuous Kinetic Assay Chapter 4
Overview 
 Most kinetic data for α-Gal is determined using either a fluorescent assay with a synthetic 
substrate MUG (32) or a colorimetric assay with a synthetic substrate para-nitrophenyl-α-D-
galactopyranoside (PNPG) (3).  These assays utilize a method of termination of the reaction with 
the presence of a base and varying time points to determine the rate of the reaction.  Although 
effective, this method has many limitations such as a low limit to the amount of substrate 
concentrations used in a saturation curve and many opportunities for human error.  Previous 
work has developed a continuous assay using MUG that allows for rate of reaction to be 
determined in real time by a plate reader decreasing the human error element (60).  The issue 
with this method was the intensity of the fluorescent product, MU, in acidic pH which is 
necessary for the reaction to occur, is ten-fold lower than in basic pH.  This difference in 
intensity often makes the determination of kinetic parameters difficult to compare to the time 
point method in basic pH.  This research presents optimization of a continuous assay with MUG 
for more rapid and accurate measurements of kinetic parameters of human α-Gal. 
Methods and Materials 
Identification of Optimal Wavelengths for Excitation and Emission 
 The substrate (MUG) and the product (MU) of the assay were scanned in both 0.1 M 
sodium acetate pH 4.6 and 0.1 M diethylamine pH 11 using a Hitachi U2910 UV-
VIS spectrophotometer from 200-600 nm to determine the wavelength of maximum absorbance 
and to identify the optimum excitation wavelength. These results were then confirmed with a 
PerkinElmer LS 55 Fluorimeter excitation wavelength scan at an emission of both 380 nm and 
445 nm, the maximum emission peaks for MUG and MU respectively. The samples were then 
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subjected to an emission wavelength scan in the same solutions using a PerkinElmer LS 55 
fluorimeter from 300-700 nm at the excitation wavelengths determined from the 
spectrophotometer. 
Development of a Continuous Enzyme Assay 
 Once the excitation wavelength was determined, the continuous assay was performed 
using the excitation at 360 nm and 315 nm and compared to the time point assay at high pH.  The 
assays were performed in a Tecan Infinite F200 series, and units were determined in comparison 
to a 0.5 nmole to 0 nmole standard curve of MU in the presence of MUG (Figure 30).  A unit is 
defined as the conversion of one nmole of MUG to MU in one hour. 
Results 
 The absorption scans indicated that there was a blue shift in the excitation wavelength of 
the product from 362 nm at high pH to 321 nm at low pH.  This result explains the decrease in 
emission observed in the assay because the excitation peak was initially determined in high pH.  
The substrate absorbs at 317 nm regardless of the pH, which means that at low pH both MU and 
MUG are excited at the same wavelength, but with different molar extinction coefficients (Table 
21), the spectra are displayed in Figures 32-33 (all spectra figures located in the appendix).  Per 
mole, MU absorbs approximately 1,000 fold more light in the 317-321 nm range than MUG, 
however in an enzyme assay the substrate (MUG) is always in greater excess than the product 
(MU), approximately 10
6
 fold more.  The results of the excitation scan are summarized in Table 
22 and the spectra are located in Figures 34-35. 
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Table 21. Absorption scan summary obtained from 
the  spectrophotometer 
MUG/MU pH 
Wavelength 
max 
Molar extinction 
coefficient (10
-6
) 
MUG 4.6 318 0.015 
MUG 11 317 0.022 
MU 4.6 321 14.3 
MU 11 362 10.9 
MUG/MU 4.6 319 0.029 
MUG/MU 11 361 0.022 
Table 22. Excitation scan summary obtained from the Fluorometer 
MUG/MU pH 
Emission 
Wavelength 
(nm) 
Excitation 
Wavelength 
max 
Molar 
extinction 
coefficient (10
-
6
) 
MUG 4.6 380 316 177 
MUG 4.6 445 316 8.95 
MUG 11 380 316 68.8 
MUG 11 445 310 3.46 
MU 4.6 380 319 88,618 
MU 4.6 445 323 1,118,380 
MU 11 380 - - 
MU 11 445 362 1,504,280 
MUG/MU 4.6 380 316 166 
MUG/MU 4.6 445 323 21.4 
MUG/MU 11 380 316 76.1 
MUG/MU 11 445 364 19.0 
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 The maximum emission wavelength was independent of pH for both MU and MUG at 
445 nm and 380 nm respectively, results displayed in Figures 36-37.  A 40-fold increase in 
intensity was observed in emission of MU in low pH when excited at 317 nm as opposed to 360 
nm.  At high pH there was only a 5-fold increase intensity when excited at 360 nm as opposed to 
317 nm, all results summarized in Table 23.  This data indicates that at low pH the MU molecule 
is more sensitive to wavelength than at high pH.  The proportion of emission intensity to 
concentration of MU at low and high pH at their respective excitation optimums is comparable; 
indicating that the decrease of emission observed previously in the continuous assay is likely due 
to the wrong excitation wavelength.  
 The units calculated in the continuous assay excited at 315 nm is the same as the time 
point assay at 360 nm and both were 4-fold higher than the continuous assay excited at 360 nm.  
The results are summarized in Table 24.   In order to determine the kinetic parameters of α-Gal a 
substrate saturation curve using this method was developed.  It was observed in this assay that 
MUG inhibits the emission of MU in a concentration dependent manner, observed in Figure 30.  
This result is likely explained by the inner filter effect (61), because MUG is in extreme excess 
(2 mM versus 0.2 nM) and absorbs light at the same wavelength. 
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 In order to overcome this effect, the assay was done in 100 µL as opposed to 300 µL 
which would fill up the well, and each substrate concentration was compared to a standard curve 
containing the same concentration of MUG resulting in five standard curves for five 
concentrations of MUG.  This process allowed for the successful determination of Km, Vmax, and 
Kcat of α-Gal as seen in the previous section.  
Table 23. Fluorometer Emission Scan Summary 
MUG/MU pH 
Excitation 
Wavelength 
(nm) 
Emission 
Wavelength 
max 
Molar 
emission 
coefficient 
(10^-6) 
MUG 4.6 317 378 175 
MUG 4.6 360 374 0.55 
MUG 11 317 377 67.6 
MUG 11 360 444 0.49 
MU 4.6 317 445 1,094,480 
MU 4.6 360 443 26,504 
MU 11 317 447 285,980 
MU 11 360 445 1,475,560 
MUG/MU 4.6 317 377 163 
MUG/MU 4.6 360 374 0.6 
MUG/MU 11 317 379 80.4 
MUG/MU 11 360 449 18.6 
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Table 24. Comparison of assays 
  Continuous Assay Exact Enzyme Assay 
  Ex 360nm Em 465nm Ex 315nm Em 450nm Ex 360nm Em 465nm 
Gain Setting Manual 50 Optimized 76 Optimized 39 
Units/mL 601 2,582 2,610 
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Figure 30. Fluorescence detection of MU in Varying MUG concentration. 
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Discussion 
 The pKa value for MU is between 7 and 8 and previously it was reported that only the 
deprotonated species was fluorescent (62).  The structure of the protonated form is displayed in 
Figure 31.  Fluorophores are typically observed in aromatic molecules due to conjugation 
observed in the delocalized pi electrons.  From first principles, the protonation in no way 
changes the aromaticity of the molecule so it should remain fluorescent.  It has been previously 
reported that the excitation wavelength for deprotonated phenols is red shifted or larger than their 
protonated counter parts(63).  Our results are consistent with this previous finding, although MU 
is not a phenol it requires higher energy light to excite the protonated species. 
 The identification of the blue shift of the 
excitation wavelength maximum of MU in low pH from 
360 nm to 320 nm allows or a much more precise and 
more automated assay to determine the activity of α-
Gal.  This discovery enables the construction of an 
accurate continuous assay that can be compared to the 
time point assay that is currently widely used in literature.  There has been a previous report of 
this blue shift finding of the excitation MU and the development of a continuous cuvette assay, 
however this has only been utilized in plant science and requires much larger volumes(64). 
 The applications of this assay expand past laboratory research on α-Gal, because MU is a 
fluorophore used as the product of many artificial substrates for enzymes involved with other 
lysosomal storage disorders.  A list of these disorders and the substrates that are used to analyze 
them is located in Table 25.  This technology can therefore be adapted to quickly screen for any 
one of those disorders in conjunction with the already developed dried blood spot technique (65).  
 
Figure 31. Structure of MU from 
Sigma Aldrich catalog 
87 
 
Currently, infants are screened for phenylketonuria(66) and Pompe disease(67) at birth which 
has drastically increased positive patient outcomes. This method can be utilized as a cost 
effective method to screen infants at birth for these genetic disorders in order to provide the best 
care for these patients as soon as possible and greatly improve the quality of their care.   
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Table 25. Methylumbelliferone (MU) based enzyme assays for lysosomal storage disorders. 
Substrate Enzyme Disease/Application Ref 
MU-α-D-galactoside Human α-galactosidase A Fabry disease (68) 
MU-β-D-lactopyranoside β-Galactosidase  
  
GM1-gangliosidosis, 
Morquio disease type B 
(69) 
MU α-D-mannopyranoside Lysosomal acid α-
glucosidase 
Glycogenosis type II 
(Pompe disease) 
(70) 
MU-palmitate Acid lipase Lysosomal acid 
lipase  (Wolman disease) 
(71) 
MU-β-D-mannopyranoside β-Mannosidase  
 
Carbohydrate-deficient 
glycoprotein syndrome 
type I 
(72) 
MU-β-D-galactopyranoside-6-
sulfate 
Galactose-6-sulphate 
sulphatase 
Morquio disease type A (73) 
MU-6-thiopalmitoyl-β-D-
glucoside  
Palmitoyl protein 
thioesterase-1  
Infantile neuronal ceroid 
lipofuscinosis (Batten 
Disease) 
(74) 
 
MU-β-D-glucopyranoside  Glucocerebrosidase  Gaucher disease (75) 
MU-α-D-glucopyranoside 
 
Human lysosomal α- 
glucosidase 
Pompe disease (76) 
MU-2-acetamido-2-deoxy-β-
D-glucopyranoside 
Human lysosomal β-
hexosaminidase A  
Tay-Sachs disease 
 
(77) 
4-Methyl-MU-Gal-6-S Arylsulfatase B Mucopolysaccharidose 
type VI 
(78) 
MU-α-L-iduronide 
 
α-L-Iduronidase 
 
Mucopolysaccharidosis 
type I (Hurler, Schelie 
syndromes) 
(79) 
MU-sulfate Arylsulfatase 
 
Maroteaux-Lamy 
syndrome (MPS VI) 
(80) 
MU-β-D-glucuronide β-Glucuronidase (Human) Mucopolysaccharidosis VII 
(Sly syndrome) 
(81) 
 
MU-2-acetamido-2-deoxy-3, 
4,6-tri-O-acetyl-β-D-
glucopyranoside  
Hyaluronidase 
 
Mucopolysaccharidosis 
type IX (Natowicz 
syndrome) 
(82) 
MU-6-sulfo-2-acetamido-2-
deoxy-β-D glucopyranoside 
N-Acetylglucosamine I -
phosphotransferase 
Mucolipidosis II and III (83) 
MU-α-D-N-acetylneuraminate Sialidase Mucolipidosis I (84) 
6-Hexadecanoylamino-MU-
phosphorylcholine 
Sphingomyelinase 
 
Nieman-Pick A and B (85) 
MU-2-acetamide-2-deoxy-α-
D-galactopyranoside  
α-N-
Acetylgalactosaminidase 
Schindler disease (86) 
MU-sulfate 
 
Iduronate-2-sulfatase Mucopolysaccharidosis 
type II (Hunter Syndrome) 
(87) 
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 Conclusions and Future Studies Chapter 5
 The need for an improved therapy for Fabry disease is significant.  The only currently 
available treatment is ERT, of which only Fabrazyme (Genzyme) is FDA approved.  However, 
both Fabrazyme and Replagal (Shire) are available worldwide.  Both of these therapeutics result 
in severe immune responses and are produced in mammalian cell lines making them extremely 
expensive.  There are clinical trials underway for additional ERTs such as moss-agal produced 
by Greenovation Biopharmaceuticals and pegunigalsidase alfa produced by Protalix.  Moss-agal is 
produced in moss, which results in mannose terminated glycosylation, same as P. pastoris, and has 
shown improvement in uptake in disease relevant cells (14).  Pegunigalsidase alfa is produced in 
tobacco, which also is mannose terminated, is chemically crosslinked with polyethylene glycol and 
has shown to be more stable and have an increased half-life in plasma (25). 
 In addition to ERT, molecular chaperones such as Migalastat produced by Amicus 
Therapeutics, are in late stage clinical trials and may be approved soon.  The benefits to 
chaperone therapy are the ability to treat tissues that are unable to take up current ERTs such as 
the kidneys and brain, however the drawback is chaperone treatment only works for specific 
mutations in the GLA gene (26).  Substrate reduction therapy such as Ibiglustat also produced 
by Genzyme, is another treatment currently in clinical trials.  Both Ibiglustat and Migalastat are 
small molecules and not a biologic; Ibiglustat inhibits the production of Gb3 (27) while Migalastat 
increases the clearance of Gb3 like ERT.  Earlier this year a patient was treated with gene therapy 
for Fabry disease, which has been explored in the past (29). 
 The goal of this research is to develop a possible candidate for ERT for Fabry disease.  This 
goal was investigated in two methods: the production of functional α-Gal in a more economical 
host such as E. coli or P. pastoris; and the use of protein engineering to construct a more 
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functional enzyme.  Initial work was done to produce a functional human α-Gal in E. coli.  
However, despite many different manipulation methods such as mutations to allow disulfide bonds 
to form and integration of an additional plasmid that coded for the production of tRNAs more 
commonly used in humans, E. coli was unable to produce an active enzyme (Chapter 2).  Prior to 
this research’s work, active α-Gal was successfully produced from P. pastoris in this lab (32, 53).  
This work set out to modify key areas for potential improvement to the enzyme using the known 
crystal structure (2), catalytic mechanism (1), and bioinformatics techniques such as primary 
sequence alignment and homology modeling.  The three locations targeted for mutagenesis were 
the active site, the dimer interface, and the hydrophobic loop between the active site and the third 
glycosylation site. 
 Throughout the course of this investigation 22 mutations were introduced into the cDNA of 
human α-Gal, of which 20 were integrated and expressed in P. pastoris (Chapter 3).  Of the twenty 
expressed mutants, eleven were cultured in shake flasks and the purification and characterization of 
eight was successful.  Of that eight, only three (W277C, Y207W, and E203C/Y207W) and one 
additional derivation of another mutant (M208E) were selected for production in the bioreactor.  
Two of these candidates, M208E and W277C, increase the catalytic efficiency of the enzyme.  
M208E increases kcat/K0.5 3-fold, while retaining comparable stability to the wild type.  W277C 
increases kcat/K0.5 2-fold, while retaining comparable if not improved stability to the wild type, and 
demonstrates an observed structural change on a native PAGE and a significantly positive 
cooperative binding phenomena.  Y207W may prove to also increase catalysis when an improved 
purification method has been developed (Chapter 3).  To better evaluate the kinetics of all the 
mutants investigated, an improved continuous enzyme assay was developed, which in addition to 
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being a very useful laboratory technique has potential to have clinical applications for screening of 
lysosomal storage disorders (Chapter 4). 
 The future directions of this research include the further characterization of the W277C, 
M208E, and Y207W mutants.  The sigmoidal substrate saturation curve of particularly, W277C 
should be further investigated, and should include exploration into the potential activation at the 
secondary binding site as well as a crystal structure to identify the structural change to the enzyme.  
The catalytic mechanism of M208E could be further examined to identify the locations of the 
deviations between this mutant and the wild type.  An optimized purification procedure for Y207W 
should be developed, and from there investigation into the kinetics again.  Another mutation worth 
constructing is a glycosylation intact F211X to determine if the increase in catalysis could be 
conserved while retaining the stability as was shown with M208E. 
 In addition to continued biochemical characterization, M208E and W277C should be 
investigated for cellular uptake in endothelial cells.  Another modification to consider is the 
integration of these mutations into a humanized P. pastoris strain which would amend the 
glycosylation to render the protein less immunogenic than the current stain (88).  In the event that 
these experiments prove successful, a Fabry mouse (89) or rat (90) study would be the next logical 
step.  If extensive preclinical research proves successful, these mutants could potential enter 
clinical trials and hopefully become effective therapeutics for patients. 
 The continuous assay should be further studied in a clinical setting.  If it proves to be useful 
for Fabry disease, it should be readapted for any or all of the disorders listed in table 25 (Chapter 
4).  If this technique can be applied in a clinical setting, it could greatly decrease the cost of testing 
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for these genetic disorders, so much so that it could be feasible to screen infants at birth to identify 
the disease as early as possible for the best potential outcome in patient care. 
  
93 
 
Appendix 
Table 26. Non-linear Regression 
Location 
of 
Mutation Mutation 
Assay Km           
(mM) 
Vmax 
(mmol/hr/
mg) 
kcat              
(1/s) 
kcat/
Km 
(1/sM) 
Relative 
kcat/Km  
to WT 
Sample 
Contents 
N/A WT 
Exact 2.09 0.019 0.46 221 1 
Concen-
trated 
Thiogal 
pool 
Continuous 
ex360nm 
0.668 
±0.026 
0.028 ± 
0.0004 
0.71 ± 
0.01 
1,064 
± 25 
1 
Continuous 
ex315nm 
1.10 
±0.06 
0.067 ± 
0.0029 
1.68 ± 
0.07 
1,525 
± 30 
1 
Interface 
W277C 
Continuous 
ex360nm 
0.56 ± 
0.04 
0.018 ± 
0.0008 
0.45 ± 
0.02 
794 ± 
23 
0.746 
Continuous 
ex315nm 
0.66 ± 
0.01 
0.016 ± 
0.0006 
0.39 ± 
0.02 
595 ± 
31 
0.390 
F273C 
Continuous 
ex315nm 
2.70 ± 
0.76 
0.008 ± 
0.0018 
0.20 ± 
0.04 
76 ± 6 0.050 
Concen-
trated SP 
pool *not 
pure/ 
unstable 
F273G/ 
W277G 
Continuous 
ex315nm 
3.21 ± 
0.68 
0.013 ± 
0.0021 
0.33 ± 
0.05 
103 ± 
5 
0.068 
Active 
Site 
E203C 
Continuous 
ex360nm 
0.98 ± 
0.17 
0.017 ± 
0.0016 
0.42 ± 
0.04 
432 ± 
34 
0.406 Concen-
trated 
Thiogal 
pool 
Continuous 
ex315nm 
1.68 ± 
0.25 
0.041 ± 
0.0048 
1.01 ± 
0.12 
604 ± 
17 
0.399 
Y207W 
Continuous 
ex360nm 
0.64 ± 
0.004 
0.079 ± 
0.0015 
1.97 ± 
0.04 
3,080 
± 157 
2.89 
Concen-
trated SP 
pool 
Continuous 
ex315nm 
0.62 ± 
.08 
0.177 ± 
0.0077 
2.93 ± 
0.19 
4,748 
± 281 
3.11 
E203C/ 
Y207W 
Continuous 
ex315nm 
1.02 ± 
0.11 
0.045 ± 
0.0017 
1.12 ± 
0.04 
1,097 
± 72 
0.84 
Glycosy-
lation 
M208E/ 
N215Q 
Continuous 
ex360nm 
0.46 ± 
0.05 
0.11 ± 
0.0015 
2.75 ± 
0.04 
5,984 
± 582 
5.62 
Concen-
trated 
Thiogal 
pool 
F211X/ 
N215Q 
Continuous 
ex315nm 
0.98 ± 
0.12 
0.207 ± 
0.0123 
5.18 ± 
0.31 
5,331 
± 360 
3.50 
Concen-
trated SP 
pool 
M208E/ 
F211H/ 
N215Q 
Continuous 
ex315nm 
1.51 ± 
0.62 
0.045 ± 
0.0147 
1.12 ± 
0.32 
756 ± 
55 
0.50 
N215Q 
Continuous 
ex315nm 
1.28 ± 
0.15 
0.019 ± 
0.0011 
0.48 ± 
0.03 
380 ± 
22 
0.25 
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Table 27. Lineweaver-Burke 
Location Mutation Assay 
Km 
(mM) 
Vmax 
(mmol/hr/
mg) 
kcat 
(1/s) 
kcat/Km 
(1/sM) 
Relative 
kcat/Km  
to WT 
Sample 
Contents 
N/A WT 
Exact 9.3 0.067 1.67 179 1 
Concen-
trated 
Thiogal 
pool 
Continuous 
ex360nm 
0.66 ± 
0.07 
0.028 ± 
0.0014 
0.69 ± 
0.04 
1,056 ± 
83 
1 
Continuous 
ex315nm 
1.64 ± 
0.06 
0.086 ± 
0.0021 
2.14 ± 
0.05 
1,305 ± 
13 
1 
Interface 
W277C 
Continuous 
ex360nm 
0.69 ± 
0.11 
0.019 ± 
0.0013 
0.48 ± 
0.03 
702 ± 76 0.665 
Continuous 
ex315nm 
1.05 ± 
0.009 
0.020 ± 
0.0018 
0.5 ± 
0.04 
482 ± 10 0.369 
F273C 
Continuous 
ex315nm 
2.13 ± 
0.38 
0.007 ± 
0.0010 
0.17 ± 
0.02 
79 ± 3 0.061 
Concen-
trated SP 
pool *not 
pure/ 
unstable 
F273G/ 
W277G 
Continuous 
ex315nm 
11.9 ± 
6.22 
0.042 ± 
0.0196 
1.04 ± 
0.49 
89 ± 4 0.068 
Active 
Site 
E203C 
Continuous 
ex360nm 
0.48 ± 
0.03 
0.012 ± 
0.0007 
0.29 ± 
0.02 
616 ± 82 0.583 Concen-
trated 
Thiogal 
pool 
Continuous 
ex315nm 
2.54 ± 
0.27 
0.053 ± 
0.0046 
1.33 ± 
0.12 
524 ± 17 0.402 
Y207W 
Continuous 
ex360nm 
0.47 ± 
0.06 
0.071 ± 0 
1.79 ± 
0 
3,869 ± 
270 
3.66 
Concen-
trated SP 
pool 
Continuous 
ex315nm 
1.03 ± 
0.05 
0.155 ± 
0.0034 
3.88 ± 
0.08 
3,774 ± 
93 
2.89 
E203C/ 
Y207W 
Continuous 
ex315nm 
1.48 ± 
0.10 
0.057 ± 
0.0045 
1.42 ± 
0.11 
961 ± 48 0.74 
Glycosy-
lation 
M208E/ 
N215Q 
Continuous 
ex360nm 
0.33 ± 
0 
0.091 ± 0 
2.29 ± 
0 
6,860 ± 0 6.50 
Concen-
trated 
Thiogal 
pool 
F211X/ 
N215Q 
Continuous 
ex315nm 
1.14 ± 
0.12 
0.228 ± 
0.0172 
5.70 ± 
0.43 
5,004 ± 
177 
3.83 
Concen-
trated SP 
pool 
M208E/ 
F211H/ 
N215Q 
Continuous 
ex315nm 
1.07 ± 
0.08 
0.035 ± 
0.0025 
0.88 ± 
0.06 
829 ± 12 0.64 
N215Q 
Continuous 
ex315nm 
3.96 ± 
1.77 
0.047 ± 
0.0183 
1.17 ± 
0.46 
299 ± 15 0.23 
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a)  
b)  
c)  
Figure 32. Absorption spectra for MUG (a), MU (b), and MUG/MU (c) at pH 4.6 
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a)  
b)  
c)  
Figure 33. Absorption spectra for MUG (a), MU (b), and MUG/MU (c) at pH 11 
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Figure 34. Excitation scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11 
(bottom) emission 380 nm. 
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Figure 35. Excitation scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11 
(bottom) emission 445 nm. 
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Figure 36. Emission scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11 (bottom) 
excitation 317 nm. 
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Figure 37. Emission scan of MUG, MU, and MUG/MU at pH 4.6 (top) and pH 11 
(bottom) excitation 360 nm. 
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